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ABSTRACT 
 
Genetic Epidemiological Characterization of Two Major Obesity Candidate Genes:  





Background: The obesity epidemic is the greatest public health problem of our time, and exerts an 
enormous health and economic burden by acting as a risk factor for multiple disorders and all-cause 
mortality. While environmental and social factors certainly contribute to the complex etiology of obesity, 
there is strong evidence of a substantial genetic component. The majority of obesity genes are involved 
the leptin-melanocortin receptor pathway governing energy homeostasis, but mutations affecting this 
circuit are often untreatable and rare, and an improved understanding of other genetic risk factors could 
aid in the development of novel therapies. In this thesis I study two obesity candidate genes with unclear 
direct relevance to disease: 1) rare structural variation at the 16p11.2 BP4-BP5 locus and 2) common 
variation in the Fat Mass and Obesity-Associated (FTO) gene.  
Methods: 1) I analyzed disinhibited eating measurements from families with 16p11.2 copy number 
variation (CNV) carriers, to test whether eating in the absence of hunger (EAH) and loss of control (LOC) 
eating behaviors mediate the dosage-dependent CNV-BMI relationship. 2) Using association data from a 
study of over 20,000 African Americans and 1,145 functional annotations from the Encyclopedia of Non-
coding Elements (ENCODE) and Roadmap Epigenomics projects, I statistically fine-mapped the FTO 
locus to identify the SNP(s) and cellular contexts underlying the association between FTO and obesity. 
Results: 1) EAH due to external triggers mediates over 30% of the 16p11.2 deletion’s effect on obesity, 
while other EAH and LOC behaviors were not significant mediators. This result was independent of IQ 
deficits and autism related to the CNV, as well as parents’ feeding behaviors and practices. 2) Given 51 
FTO SNPs’ association statistics, correlation, and overlap with functional annotations, rs9927317 and 
rs62033405 had the highest posterior probability of association with obesity. Obesity-associated SNPs 
may regulate expression of FTO and/or nearby genes through the activity of enhancers and 5’ ends of 
transcribed genes in the substantia nigra of the brain, bone chondrocytes, and white adipose. 
Conclusions: These results may help pinpoint the specific genes, regulatory elements, and cellular 
contexts through which the 16p11.2 and FTO loci exert their effects on obesity.
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Chapter 1: Introduction 
1.1 Background and Public Health Relevance of Obesity 
	
Obesity is a common and increasingly prevalent risk factor for many diseases, including Type 2 
diabetes, atherosclerosis, some forms of cancer, as well as mortality from all causes [1, 2]. Defined as 
having a body mass index (BMI) ≥ 30 kg/m2 in adults and BMI z-score ≥ 95% in children, obesity is a 
major public health problem. In the United States, over one in three adults (34.9%, totaling 78.6 million) 
are obese, while in children and adolescents the prevalence of obesity is about 17% (12.7 million) [3]. The 
projected economic burden of obesity is substantial and far-reaching. By the year 2020, annual medical 
costs of treating obesity-related disorders are projected to increase to $394-$437 billion, or 14-16% of 
health care costs in the US [4], while lost productivity attributable to obesity costs as much as $390-$580 
billion annually [5]. In comparison, by the year 2020 cancer care is projected to cost $173 billion in 2020 
[6], and lost productivity due to cancer costs $148 billion annually [7]. 
1.2 Obesity Genetics 
	
 While environmental and social factors such as sedentary lifestyle and ease of access to food 
certainly play a role in the pathogenesis of obesity, within a given environment there is substantial inter-
individual variation in body weight and predisposition to weight gain, implicating genetic risk factors [8]. 
Consistent with this notion, heritability estimates of BMI are high (h2 ~0.4-0.7) [9, 10], monozygotic twins 
(MZ) exhibit congruent responses to overfeeding and exercise [11-13], and MZ twins have substantially 
higher concordance for fat mass (70-90%) compared to dizygotic (DZ) twins [9, 14]. 
Obesity was confirmed to have a genetic basis following the identification of severe monogenic 
forms of obesity cases due to rare mutations that perturb the hypothalamic leptin-melanocortin pathway 
controlling energy balance [15, 16]. Leptin (LEP) was initially identified in mice and was the first gene 
found to underlie obesity [17]. Next, leptin deficiency was found in individuals with severe early-onset 
obesity in humans [18], affirming the existence of monogenetic obesity in humans. Subsequent 
examination of humans with extreme obesity led to the discovery of additional nodes along the leptin-
melanocortin pathway, including Leptin Receptor (LEPR) [19], Proopiomelanocortin (POMC) [20], 
Melanocortin 4 Receptor (MC4R) [21, 22], Melanocortin 2 Receptor Accessory Protein 2 (MRAP2) [15, 
23], Proprotein convertase 1 (PCSK1) [24], Brain-derived Neurotrophic Factor (BDNF) [25], the BDNF 
receptor Neurotrophic Tyrosine Kinase Receptor Type 2 (NTRK2) [26], Single-minded Homolog 1 (SIM1) 
[27], and SH2B Adaptor Protein 1 (SH2B1) [28, 29]). Additional rare variants have been implicated in 
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syndromic forms of obesity: Bardet-Biedl syndrome [30], Alstrom syndrome [31], and Prader-Willi 
syndrome [32]. 
Efforts to map additional obesity genes have yielded robust associations with both rare and 
common variants. However, it is unclear how obesity-related variants in genes outside the leptin-
melanocortin receptor pathway play a role in the pathogenesis of non-syndromic obesity. An improved 
understanding of these genes’ contribution to the pathogenesis of obesity is important for decreasing its 
public health burden, as defects in the leptin-melanocortin pathway are rare and often untreatable (i.e. 
leptin receptor hypomorphism), and these variants explain only a fraction of obesity’s genetic component. 
Mechanistic characterization of these genes could clarify their relationship with obesity, provide a model 
for studying other disease-associated genes outside of known pathways, and identify targets for 
therapeutic intervention. 
1.3 The 16p11.2 BP4-BP5 Locus and Obesity 
	
The chromosomal deletion between breakpoints 4 and 5 at the 16p11.2 locus (chr16:29,652,999 
to 30,199,351; hg19) has been consistently associated with obesity [28, 29, 33-40]. This CNV has a 
population prevalence of ~1/2000, and spans ~600 kb and 29 genes, none of which are related to genes 
previously implicated in obesity. The phenotype of deletion carriers mirrors that of duplication carriers for 
some anthropometric parameters: on average, deletion carriers having higher BMI while duplication 
carriers have lower BMI [33]. These relationships vary with age and gender, as overweight or obesity 
associated with 16p11.2 were reported to be of juvenile onset and more severe in males [29, 35, 40]. 
However, the mechanisms by which the 16p11.2 CNV affects body weight are not clear. 
1.4 The FTO Locus and Obesity 
	
SNPs in the first intron of the FTO gene represent the strongest genome-wide significant 
associations with obesity [41], but their direct relevance to obesity pathophysiology is unclear. Obesity-
associated FTO SNPs have similar effects on BMI in European-ancestry and African-ancestry populations 
such as AAs: risk alleles increase BMI by 0.39 kg/m2 and 0.41 kg/m2, respectively. However these SNPs 
explain more BMI variance in Europeans (0.34%) than AAs (0.10%), in part due to higher minor allele 
frequencies in Europeans (~43%) compared to AAs (~12%) [42, 43]. In European populations, which 
have been the focus on most genome-wide association studies (GWAS) conducted to date, the SNPs are 
indistinguishable due to the high levels of linkage disequilibrium (LD) [44]. Interestingly, the FTO SNPs 
associated with obesity in Europeans and AAs are mutually exclusive [41]. While both groups of SNPs 
are in LD among Europeans, in AAs each group of SNPs belongs to an independent LD cluster (Table I). 
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These LD patterns can be explained by the two groups’ distinct population genetic histories. AAs 
represent an admixture of previously isolated Africans, Europeans, and other groups due to the 
transatlantic slave trade in the United States. Africans are the oldest of modern human populations in 
evolutionary terms, and have experienced more generations for LD to decay via recombination compared 
to the genomes of other ancestral groups [45]. Due to population admixture, AAs’ chromosomes also 
represent a mosaic of chromosomal blocks from distinct ancestral subpopulations [46]. In contrast, 
European genomes have undergone less recombination, and therefore have higher levels of LD, low 
haplotype diversity, and low levels of population structure (population stratification and hidden 
relatedness) [47]. In addition, ancient bottlenecks associated with Out-of-Africa migrations have resulted 
in reduced haplotype diversity among non-African populations compared to African-Ancestry groups [48-
53].  
The second chapter of this thesis will discuss and synthesize the current literature describing two 
loci with strong and robust associations with obesity, but unclear pathophysiological relevance: 1) rare 
copy number variations (CNVs) at the 16p11.2 BP4-BP5 locus and 2) common single nucleotide 
polymorphisms (SNPs) in the first intron of the Fat Mass and Obesity-Associated (FTO) gene. Chapter 3 
will describe an analysis of relationships between the 16p11.2 CNV, disinhibited eating behaviors, and 
obesity, including a formal mediation analysis. Chapter 4 will detail my efforts to fine-map obesity-
associated SNPs at FTO locus in African Americans (AAs). The concluding chapter will provide a 
summary of my thesis research and provide future directions. 
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Chapter 2: Systematic Literature Review 
2.1 Abstract 
	
I performed systematic reviews of the primary scientific literature describing relationships 
between human obesity and A) structural genetic variation at the 16p11.2 BP4-BP5 locus and B) common 
genetic variation at the FTO locus in African American (AA) populations. After identifying potentially 
relevant articles using broad search criteria, I systematically evaluated all articles’ titles and abstracts, and 
focused on articles directly relevant to my thesis aims (6 articles regarding the 16p11.2 CNV and 25 
articles about FTO in AAs). I found robust evidence of an association between the 16p11.2 deletion and 
obesity. To date, the mechanism of this relationship has not been elucidated, but some data suggest that 
eating behaviors may play a role. After excluding underpowered studies of FTO in AAs, as well as those 
with inappropriate adjustments for ancestry or studies that pooled across ethnicities to maximize 
statistical power at the expense of identifying ancestry-specific effects, I observed ancestry-specific 
patterns of FTO SNP associations with obesity, as SNPs previously associated with obesity in Europeans 
were not significant in studies of AAs. The clustering of obesity-associated SNPs in AAs suggests that a 
variant tagged by a smaller subset of markers may be directly relevant to disease etiology, and focusing 
on AAs may aid in refining the association signal. In summary, my systematic literature review found 
strong evidence of associations between obesity with 16p11.2 CNVs and FTO SNPs, as well as 
promising avenues for further exploration: eating behaviors related to 16p11.2 genotype and obesity-
associated FTO SNPs from well-conducted and well-powered studies of AAs. 
2.2 Methods: Selection of Articles 
	
Informed by criteria from Preferred Reporting Items for Systematic reviews and Meta-Analyses 
(PRISMA) [54], I performed comprehensive systematic reviews of primary scientific research papers 
investigating the relationships between human obesity and A) structural genetic variation at the 16p11.2 
BP4-BP5 locus and B) common genetic variation at the FTO locus in African American populations. I 
focused on peer-reviewed articles published in English, removed reviews, commentaries, case reports, 
duplicates, as well as meta-analyses across studies (I retained meta-analyses across datasets), restricted 
to population-based human-subjects studies, and also reviewed studies identified through citations from 
relevant articles. Search and additional exclusion criteria for each topic are described below. 
For all studies I noted the first author, year, title, source population, study sample size, study 
design, ethnicities represented, analytic approaches, genotyping methods and FTO SNPs 
genotyped/associated with obesity (for FTO papers), outcome measures, covariates, ancestry adjustment 
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approaches (for FTO papers), and results directly relevant to each aim. Using the identified articles I 
wrote a systematic review article describing the importance and relevance of studying the relationships 
between obesity and the 16p11.2 BP4-BP5 and FTO loci, synthesized the literature to identify knowledge 
gaps regarding their relationships with human obesity, and highlighted relevant previous studies’ 
methodological aspects (both positive and negative) and results to justify my dissertation’s hypotheses 
and the specific aims designed to answer these questions. 
2.3 The 16p11.2 BP4-BP5 CNV and obesity 
2.3.1 Search Criteria 
	
I reviewed all articles identified in PubMed using the keywords “16p11” and “obesity,” “BMI”, or 
“adiposity.” Since CNVs at 16p11.2 are rare (~1/2000), some of the earlier publications were case 
reports, rather than population-based, and were excluded. 
2.3.2 Screening 
	
The search criteria I used yielded 45 unique papers published between June 1992 and 
September 21, 2015. As structural variations at the 16p11.2 locus were among the first-identified 
pathogenic CNVs, numerous studies mentioned 16p11.2 CNVs to justify their research, but 1) did not 
actually study this CNV, 2) did not actually study obesity, or 3) involved genome-wide screens for obesity-
associated CNVs but did not report results relevant to 16p11.2 CNVs. I also excluded the manuscript I 
published in October 2014 detailing some of the analyses that will be described in Chapter 3. I will 
therefore focus my discussion on the 6 population-based studies that contributed insight regarding obesity 
and structural variation at the 16p11.2 BP4-BP5 locus (Figure 1). 
2.3.3 Literature Review 
	
 Below I describe in chronological order my systematic review of articles regarding the relationship 
between the 16p11.2 BP4-BP5 CNVs and obesity. Bochukova et al. [28] and Walters et al. [29] were the 
first to report associations between CNVs at 16p11.2 and obesity in February 2010. In both studies, the 
investigators used DNA microarrays to screen for structural variations in children ascertained for both 
extreme obesity (BMI z-score ≥3.0) and developmental delay, and identified an excess of CNVs at 
16p11.2 compared to general population controls matched for ancestry. Notably, multiple 16p11.2 CNVs, 
some overlapping, were overrepresented in obese cases: 1) 600-kb deletions between breakpoints 4 and 
5 in this region (BP4-BP5), which were previously identified in individuals with autism and developmental 
delay [36-39]; 2) 220-kb deletions between the second and third breakpoints (BP2-BP3) which contain the 
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SH2B adaptor protein 1 (SH2B1) gene encoding a protein likely involved in leptin signaling given the 
phenotypic similarities between 16p11.2 BP2-BP3 CNV carriers and LEPR-deficient individuals [28]; 3) 
deletions spanning both of the above regions (BP2-BP5). In addition, Walters et al. found that the obesity 
phenotype was stronger in adult deletion carriers, suggesting an age-dependent penetrance that was also 
observed in subsequent studies [33, 40] that also found more severe phenotypes in males. 
 Next, Jacquemont et al. [33] published the largest study of the 16p11.2 BP4-BP5 CNV to date, 
pooling multiple cohorts with different ascertainment criteria: neurodevelopmental disorders (31,424), 
family history of adult psychiatric symptoms (1,080), underweight or obesity (3,544), and population-
based controls (58,635), all of European ancestry. This study was the first to show robustly that 16p11.2 
BP4-BP5 duplications lead to underweight, suggesting a dose-response relationship between 16p11.2 
genotype and body weight. The small number of duplication carriers described in Walters et al. [29] did 
not exhibit obesity or hyperphagia (excessive hunger or increased appetite). The authors of the larger and 
BP4-BP5-focused study also observed parallel effects of the CNV on of head circumference, with deletion 
carriers having a higher risk of macrocephaly and duplication carriers having increased risk of 
microcephaly [33]. 
 Zufferey et al. [35] published the first comprehensive study of families, which were ascertained for 
16p11.2 BP4-BP5 CNVs by the Simons Variation in Individuals Project (VIP) consortium. In analyses 
restricted to deletion carriers, the authors replicated the association between the BP4-BP5 deletion with 
obesity, and observed hyperphagia in all 14 deletion carriers in which eating behavior was measured, 
increased head circumference independent of BMI, as well as decreased full-scale IQ, by an average of 2 
standard deviations, in both male and female deletion carriers. 
 Despite the robust association between gene dosage at 16p11.2 and BMI, especially deletions 
with obesity, the mechanism of this relationship is unclear. Recently, two studies found evidence to 
suggest that eating behavior may be altered by 16p11.2 CNVs. 
Maillard et al. [55] conducted nuanced phenotypic analyses corroborating the observations of 
hyperphagia in deletion carriers, suggesting that the genotype-phenotype relationship may be 
behaviorally mediated. The authors studied gene expression and brain volume data derived from 
magnetic resonance imaging (MRI) in BP4-BP5 deletion and duplication carriers. Overall, the authors 
found that copy number at 16p11.2 had a dose-response relationship with changes in brain anatomy, 
which may underlie deletion-related macrocephaly and duplication-related microcephaly. Notably, deletion 
carriers had enlarged brain regions related with eating behavior (striatum, medio-dorsal thalamus, orbito-
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frontal cortex, and insula), while reciprocal effects were observed in duplication carriers. Gene expression 
data were consistent with genotypic data suggesting a gene dosage effect. 
 CNVs were discovered just over a decade ago, and the 16p11.2 locus even more recently. As a 
result, there is not an abundance of literature regarding the 16p11.2 CNV’s relationship with obesity, 
although most studies are well powered. Given the low frequency of these genetic lesions, some 
investigators needed to pool multiple datasets to find an association, including genotypic data from 
general population controls. However, robust evidence of the association has been found in additional 
studies such as the Simons VIP, in which CNV carriers were matched to non-carrier relatives. 
 In summary, the 16p11.2 BP4-BP5 deletion has been consistently associated with obesity, and 
duplication carriers tend to be underweight. From the articles reviewed above, anthropometric and brain 
imaging data, along with observations of hyperphagia, suggest that the relationship between deletions 
and obesity may be behaviorally mediated. For my thesis, I will directly test this hypothesis using Simons 
VIP family data. 
2.4 The FTO locus and obesity in African Americans compared to Europeans 
2.4.1 Search Criteria 
	
I reviewed all PubMed articles retrieved using the keywords “FTO and African Americans and 
obesity,” “FTO and European(s) and obesity,” “FTO and African Americans and BMI,” “FTO and 
European(s) and BMI,” “FTO and African Americans and adiposity,” and “FTO and European(s) and 
adiposity.” Since the full name of the FTO gene contains the word obesity, the above search terms 
yielded papers about FTO with no relevance to obesity, which were excluded.  
2.4.2 Screening 
	
The goal was to identify papers describing the FTO locus in AAs, but the search terms included 
“European” and “Europeans” in order to capture articles about AAs but discussing SNPs associated with 
obesity from studies of Europeans. This search yielded 205 unique papers published between July 20, 
2007 and August 20, 2015. I focused my literature review on the 25 papers that studied both Europeans 
and AAs, only AAs, or other African-ancestry groups only, as the papers reporting FTO association 
results focused on Europeans are numerous, consistent, and well-documented, but not informative for 
identifying association and LD patters that distinguish Europeans and AAs. I also excluded publications 
regarding populations other than Europeans and African Americans, as the contrasts in LD and obesity 
GWAS result patterns are clearest when comparing SNPs identified in studies of these two ancestral 
groups (Figure 2). 
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2.4.3 Literature Review 
	
 Table II summarizes my systematic review, in which I evaluated 25 papers. The authors of these 
studies either performed candidate SNP, candidate gene, or genome-wide association studies of obesity 
that included AAs. At first glance, the reports appeared to show inconsistent results. For example, SNPs 
previously associated with obesity in Europeans (rs9939609, rs8050136, rs17817449, rs9930506) 
reached statistical significance in some studies of AAs [56-63] but not others [64-76], while some found 
no association with any measured FTO SNP [69, 71-73, 77]. However, upon closer inspection, one or 
more of the following study flaws appear to underlie the inconsistent association trends: 1) heterogeneity 
in the ancestral composition of the study population owing to a) improper adjustment for population 
stratification or b) meta-analyses across multiple ethnic groups to maximize power at the expense of 
combining ethnically heterogeneous datasets, and 2) insufficient statistical power due to small sample 
sizes (1000 or less). 
Population stratification due to admixture arises when a population comprises subpopulations 
with unique demographic histories and distinct disease and allele frequencies. Systematic differences in 
cases’ and controls’ allele frequencies due to ancestry, rather than disease status, could confound 
associations between genotype and phenotype [78-80]. Accordingly, investigations involving the analysis 
of genotypes in AAs require appropriate adjustments to account for possible heterogeneity arising from 
differential admixture. Eight of the reviewed studies took problematic approaches to ancestry adjustment 
[57, 58, 61-63, 65, 73, 81], which may have contributed to their failure to identify ethnicity-specific 
clustering of SNP associations shown in Table I. Specifically, despite the presence of potentially 
differentially admixed AAs as well as non-AAs in their study populations (Europeans, Nigerians, South 
Asians, and Hispanics), the authors did not stratify their analyses by race, and consequently either failed 
to find associations between obesity with any FTO SNPs [65, 73], found associations for SNPs from 
studies of Europeans [57, 58, 81], or found associations for obesity-associated SNPs from studies of both 
Europeans and African-ancestry populations [61, 62, 76]. Two of these papers were completely missing 
adjustments for ancestry in the analysis [63, 65], while two others performed trans-ethnic meta-analysis in 
study populations that were predominantly of European descent, in an effort to maximize statistical power 
by pooling across ethnicities, but in doing so precluded the detection of ethnicity-specific association 
clusters [62, 81]. In short, when studying genotype-phenotype relationships using AAs, and especially 
when the study population includes non-AAs, it is important to perform adjustments for confounding by 
differential admixture as well as stratified analyses in order to identify ethnicity-specific associations at the 
FTO locus. 
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FTO SNPs identified from GWAS of Africans have lower minor allele frequencies (~0.09) 
compared to SNPs identified from GWAS of AAs (~0.42). Therefore, in addition to appropriate ancestry 
adjustments, large samples of AAs are needed to detect associations between FTO SNPs identified from 
GWAS of Africans. Not surprisingly, insufficient statistical power was another reason for the inconsistent 
findings in studies that included AAs. In some reports improper adjustments for ancestry compounded the 
problems associated with small sample size [57, 61, 63, 65, 73]. Among the underpowered studies with 
adequate adjustment for and stratification by ethnicity, all still failed to identify associations with African 
obesity-associated FTO SNPs [59, 60, 64, 69, 71, 72, 75-77, 82], while two reports found associations 
with some European obesity-associated FTO SNPs [59, 60]. The lone study that sequenced the entire 
FTO gene was also underpowered and found no non-synonymous variants associated with obesity, 
although its focus was on exons while all obesity-associated FTO SNPs are intronic [82]. Interestingly, in 
two of the underpowered studies, the authors found no associations of obesity with SNPs previously 
associated with obesity in Europeans (rs9939609, rs8050136, rs9930506, rs17817449) [64, 75], but did 
not find ethnicity-specific associations either, since African FTO SNPs such as rs1421085 and rs3751812 
were not genotyped. The best of the underpowered studies was conducted by Hester et al., who were the 
first to study FTO SNPs in well over 1000 AAs (N=4,992), and found that SNPs previously associated 
with obesity in Europeans (rs9939609 and rs9930506) were not significantly associated with obesity in 
AAs, while the association for rs1421085 almost reached statistical significance in this study (p=0.07) 
[72]. 
Two additional studies had reasonably large sample sizes and were ethnically homogeneous, but 
did not identify ethnicity-specific associations. Demerath et al., only genotyped rs9939609, and this SNP 
was associated with obesity in Europeans but not AAs. The authors also reported significant effect 
modification of the genotype-phenotype association by physical activity in both ethnic groups [67]. 
Another study by Hennig et al. genotyped 16 FTO SNPs, including markers associated with obesity in 
Europeans (rs8050136 and rs17817449) and AAs (rs3751812) in over 2000 Gambians, but found no 
association since this population was not exposed to excess food and had a very low obesity rate (>75% 
were lean) [71]. In brief, the studies by Demerath et al. and Hennig et al. identified important 
environmental factors that may affect the penetrance of FTO genotypes. 
 In contrast with the studies described above, the papers that 1) had large numbers of AAs, 2) 
genotyped obesity-associated SNPs from associations studies of both Europeans and AAs, 3) separately 
analyzed AAs and non-AAs, and 4) properly adjusted for ancestry in AAs consistently found ethnicity-
specific association patterns: significant associations for SNPs associated with obesity in AAs (rs1421085 
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and rs3751812) but not SNPs associated with obesity in Europeans (rs9939609, rs8050136, and 
rs17817449) [42, 56, 66, 68, 70, 74]. 
In summary, this review of the population-based examinations of FTO and obesity in AAs 
confirmed my preliminary analyses identifying ethnicity-specific clusters of SNPs at this locus: one group 
of SNPs associated with obesity in Europeans, which are not associated with obesity in AAs, and a 
second group of SNPs associated with obesity in AAs but not in Europeans. My second dissertation 
project will focus on fine-mapping obesity-associated SNPs in AAs, as these markers may represent a 
refined set of markers tagged by a truly disease-related variant, and studying AAs may increase the 
probability of finding this SNP.  
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Objective: The ~600-kb BP4-BP5 16p11.2 deletion has been consistently associated with obesity. I 
studied two heritable disinhibited eating behaviors, eating in the absence of hunger (EAH) and loss of 
control (LOC), to better characterize the relationship between the deletion and obesity. 
Design and Methods: The study population included ninety-three 16p11.2 CNV carriers (64 with deletions 
and 29 with duplications) and their families. I focused on deletion carriers and performed analyses using 
linear mixed models, as well as formal mediation analyses to quantify direct and indirect effects of the 
deletion on BMI and EAH behaviors. 
Results: I confirmed the previously discovered relationship between the 16p11.2 deletion and obesity 
(p<0.0001), and identified a significant association between the deletion and EAH due to external cues 
(p=0.02) and as well as a nominal association with EAH due to boredom (p=0.06). I also found significant 
relationships between obesity with EAH external (p=0.0001) and EAH boredom (p=0.001) that were 
independent of 16p11.2 genotype. Using mediation analysis I discovered a significant indirect effect of the 
16p11.2 deletion on obesity through EAH external (p<0.0001) which explains over 31% of the CNV’s 
effect on BMI. Obesity attributable to the 16p11.2 deletion also accounted for over two-thirds of the 
association between the deletion and EAH external (p=0.01). LOC was underrepresented and unrelated 
to the deletion. 
Conclusions: I report evidence that EAH due to external trigger may account for over 30% of the 16p11.2 
deletion-obesity association. Prospective studies are needed to confirm the temporal order of EAH 





Copy number variations (CNVs) between breakpoints 4 and 5 at the 16p11.2 locus 
(chr16:29,652,999 to 30,199,351; hg19) have an inverse dose-response relationship with BMI:  deletion 
carriers are at increased risk of obesity, while duplication carriers are more likely to be underweight [33].  
The CNV has a prevalence of ~1/2000 in European ancestry populations, and spans a ~600 kb 
containing 29 genes. Age and gender are effect measure modifiers of the relationship between BMI and 
both deletions and duplications [29, 35, 40]. However, based on current knowledge it is not clear how the 
16p11.2 BP4-BP5 CNV affects body weight. 
Disinhibited eating is characterized by a loss of restraint over food intake and encompasses binge 
eating disorder (BED), loss of control (LOC) over eating, emotional eating, and eating in the absence of 
hunger (EAH), in order of decreasing severity and increasing prevalence [83]. The more severe behaviors 
include symptoms of the milder forms of disinhibited eating. EAH involves eating palatable foods when 
not feeling physiologically hungry in response to emotional (sad or depressed, angry or frustrated, 
anxious or nervous, tired, and bored) and external (sensory and social cues) triggers during and after 
meals, and may increase the risk of obesity [84-86]. LOC over eating is defined as the subjective 
experience of losing control over eating and is similar to BED except that it does not necessarily involve 
consumption of a large amount of food. Both LOC and BED are more prevalent in overweight compared 
to non-overweight children [87-89], but the former is believed to be the more salient construct since it 
captures more children who exhibit hallmarks of severe disinhibited eating, while few youths meet 
diagnostic criteria for BED [90]. The prevalence estimates are 6-57% for binge eating, 4-45% for LOC 
eating, 50-63% for emotional eating, and 50-60% for EAH [83].  
There is evidence to suggest that disinhibited eating behaviors may have a genetic basis. In a 
study of Hispanic children, EAH was highly heritable (51%) and associated with increased risk of obesity 
and fasting leptin and insulin levels [91]. Previous work has shown that uncontrolled and emotional eating 
as well as a lack of cognitive restraint were associated with a composite genetic risk score based on the 
number of risk alleles at loci previously identified from genome-wide association studies of obesity [92]. It 
is therefore plausible that the effect of 16p11.2 structural variation on body weight may be mediated 
behaviorally, by EAH and/or LOC (Figure 3). 
In this study I examined eating in the absence of hunger (EAH) and loss of control (LOC) eating 
behaviors in a genetically well-defined population, in which obesity is associated with 16p11.2 genotype. 
The study population comprised ninety-three 16p11.2 CNV carriers and their families. Carrier/non-carrier 
comparisons were conducted within each family unit, and I used linear mixed models (LMMs) to account 
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for non-independence resulting from the inclusion of multiple individuals within families, and generate 
unbiased standard error estimates. The high penetrance of the 16p11.2 CNV as well as the availability of 
non-carrier relatives as a reference group permitted a focused examination of the CNV’s effect on eating 
behaviors and BMI. Since a parental CNV carrier could influence ingestive behaviors in the family, I also 
restricted analyses to families with a de novo deletion. The goal of this study was to determine whether 
changes in BMI due to 16p11.2 genotype are mediated by EAH and/or LOC. 
3.3 Methods 
3.3.1 Recruitment and Phenotyping 
	
Families were recruited as part of an ongoing cohort study in which families with individuals 
carrying a deletion or duplication between breakpoints 4 and 5 at the 16p11.2 locus were ascertained 
after clinical diagnostic testing [93]. Recruitment was primarily via Simons VIP Connect 
(SimonsVIPConnect.org), an online community of 16p11.2 CNV carriers and their families. Families often 
connected to the website via Internet search after they received results of a clinical chromosome 
microarray, most often to aid diagnosis of developmental delay or a birth defect, or were notified of their 
eligibility for the Simons VIP study by their treating physician or other medical professionals. Cascade 
genetic testing within the family was used to identify other carriers and to determine if the CNV was 
inherited or de novo.  
Longitudinal growth charts were obtained from primary care providers, and current height, weight, 
and head circumference were obtained by direct measurement during the clinical assessment at one of 
three centers (Baylor College of Medicine, Boston Children’s Hospital, and University of Washington). At 
the clinical evaluation, Eating in the Absence of Hunger (EAH) [94] and Loss of Control (LOC) eating [90] 
questionnaires were administered, regardless of CNV status, to children, adults, and parents, and Child 
Feeding Questionnaires (CFQ) [95] were administered to parents. Standardized IQ tests were used to 
measure full-scale intelligence quotient (FSIQ). Parents completed questionnaires for children up to age 
18, and children also reported for themselves if they were deemed capable of self-report (generally an 
FSIQ >90). Experienced clinicians with documented cross-center reliability classified subjects across the 
spectrum of autism using the Autism Diagnostic Observation Schedule (ADOS), Autism Diagnostic 
Interview–Revised (ADI-R), and DSM-IV-TR criteria. Evaluations were taped and a subset was reviewed 
at regular intervals by an outside rater to ensure continued reliability across sites. The Institutional Review 
Boards at Columbia University, Baylor College of Medicine, Boston Children’s Hospital, and University of 
Washington approved protocols. 
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3.3.2 Exclusion Criteria 
	
Participants with any other pathogenic CNVs outside of the 16p11.2 BP4-BP5 interval, other 
neurogenetic or neurological diagnoses unrelated to 16p11.2 (e.g. tuberous sclerosis), birth asphyxia, 
fetal alcohol syndrome, and/or prematurity <30 weeks were excluded from the study. I also excluded 2 
siblings with deletions due to germline mosaicism and 5 participants (2 deletion carriers and 3 duplication 




All 16p11.2 CNV probands were genotyped using clinical chromosome microarrays, confirmed 
with high resolution SNP microarrays, and had the same CNV breakpoints. Cascade genetic testing was 
conducted for all family members using a custom-designed oligonucleotide array containing genome-wide 
coverage at a resolution of ~400 kb and targeting known disease genes with coverage at a resolution of 
~50 kb (OGT 60K, Oxford Gene Technologies, Tarrytown, NY), as previously described [97], to determine 
if the CNV was de novo or inherited and to identify other deletion/duplication carriers within the family.   
3.3.4 Outcome Definitions 
Eating in the Absence of Hunger (EAH) 
	
Analyses of children’s EAH behaviors were limited to EAH questionnaires completed by parents; I 
excluded children’s self-reports in light of parental responses’ good concordance with laboratory 
assessments of EAH [98], to minimize underreporting, especially among overweight participants [99, 
100], and to avoid misreporting due to any intellectual impairments in the children. Parents’ self-reported 
responses to the EAH questionnaires were also available and considered potential confounders of their 
children’s EAH and BMI statuses. The EAH questionnaire (Appendix A.1) contained 14 items consisting 
of two sets of similar questions that probe emotional (sad or depressed, angry or frustrated, anxious or 
nervous, tired, and bored) and external (sensory and social cues) aspects of EAH behavior during and 
after meals. Parents indicated the frequency with which they or their children ate past satiation in the 
absence of hunger in response to the 7 cues, using a 5-point scale ranging from 1 (“Never”) through 5 
(“Always”) [94]. 
Loss of Control (LOC) Eating 
	
In contrast to EAH responses, LOC questionnaire (Appendix A.2) responses were restricted to 
children’s self-reported LOC eating, since this highly subjective phenomenon is not readily observable by 
parents (M. Tanofsky-Kraff, Personal Communication). Parents’ self-reported responses to the LOC 
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questionnaires were also available. Children and parents were only asked to report LOC questionnaire 
responses for themselves if they were deemed capable (FSIQ >90). A study participant was 
characterized as having had LOC eating if he or she reported A) recurrent LOC eating episodes 
characterized by a feeling of losing control over eating; B) 1) seeking food after feeling satiated or in the 
absence of hunger or 2) feeling that the amount eaten was too much at the time; C) two or more LOC 
eating episodes within the previous three months; and D) experiencing LOC eating episodes 
characterized by at least three of the following: 1) negative affect-induced eating, 2) eating in secrecy, 3) 
feeling numb or a lack of awareness during eating, 4) eating more than others or perceiving this to be 
true, and 5) negative feelings (e.g. shame or guilt) after eating [90]. 
Child Feeding Practices 
	
The parental feeding practices restriction and pressure to eat have been associated with both 
disinhibited eating and BMI [101]. The Child Feeding Questionnaire (CFQ) (Appendix A.3) contained 31 
items corresponding to the following constructs: perceived responsibility, perceived parent weight, 
perceived child weight, concern about child weight, restriction, pressure to eat, and monitoring [95]. 
Parents indicated their agreement with questions probing their tendancy to restrict their children’s food or 




For all measurements taken between ages 2 to 20 years, I used the 2000 CDC growth charts to 
calculate age- and gender-specific BMI z-scores [102]. On average, 4.3±6.8 (range 1–39) growth 
measurements were available for each subject. For the present analyses, I used BMI z-scores at the time 
feeding questionnaires were administered, as most growth measures were retrospectively obtained from 
medical records. 
3.3.5 Statistical Analysis 
	
I performed factor analyses with promax rotations on EAH and CFQ scores to determine whether 
latent variables underlie groups of responses and to reduce the number of variables per subject for later 
analyses [77, 103]. For each item in a questionnaire, the squared multiple correlation with all other 
variables was used to estimate the prior communalities, which represent the proportion of an item’s 
variance that is both shared with other items in the questionnaire and error-free (i.e. explained by the 
latent variables only). The communalities were then substituted along the diagonal of the correlation 
matrix of questionnaire items, and the principal axis factoring method was used to extract factors 
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underlying groups of responses. The scree plot and residuals were analyzed to determine the number of 
factors. Standardized factor scores on a z-score scale ranging from -3.0 to 3.0 were generated for each 
EAH and CFQ factor. Cronbach’s alpha values were calculated for items represented by each factor to 
evaluate their internal consistency and identify candidate items for exclusion from subsequent analyses.  
Descriptive statistics are presented as frequencies, percentages, means, and standard 
deviations. To compare mean age, BMI z-score, full-scale IQ, and EAH scores between CNV carriers and 
non-carriers, I used bivariable linear mixed models (LMMs) [104] in deletion families and the Wilcoxon 
Rank Sum Test in duplication families due to the small sample size.  
I first confirmed the known association between 16p11.2 genotype and BMI. Next, I tested 
whether 16p11.2 deletions and duplications were associated with EAH and/or LOC eating in children. 
Lastly, I examined whether disinhibited eating behaviors were related to BMI by regressing BMI on both 
disinhibited eating and genotype, to confirm whether BMI and eating behaviors were associated 
independent of 16p11.2 genotype [105]. I stratified my analyses by CNV type (deletion or duplication) and 
used random intercept LMMs to examine relationships between 16p11.2 CNV carrier status, EAH 
behaviors, LOC behaviors, parental feeding practices as well as parents’ own EAH behaviors, FSIQ, and 
BMI z-scores while accounting for the effect of family. Some LMMs were also fitted using a random slope 
to account for inter-family variations in the effect of genotype on BMI z-scores or EAH, if the random slope 
was significant. In all analyses that included 16p11.2 genotypes, I adjusted for effect modification by age 
and gender. Based on past studies of the 16p11.2 locus and anthropometric traits, the CNV is penetrant 
after age 5. I also pooled the deletion and duplication families and coded genotype as a 3-level variable 
(3 copies vs. 2 copies vs. 1 copy) and repeated the analyses described above, in an attempt to increase 
the statistical power to detect an effect of duplications on EAH, LOC, and BMI, as well as test for an 
additive effect of gene dosage on these outcomes. I repeated all analyses after restricting to de novo 
CNV carriers, as parental genotype could confound the deletion-eating behavior relationship. 
In situations where the above statistical tests were significant, I performed mediation analyses to 
quantify the pure natural direct and total natural indirect effects (via eating behaviors) of 16p11.2 CNVs on 
BMI. I used the SAS macro from Valeri and Vanderweele [106] to estimate these direct and indirect 
effects. The pure natural direct effect represents the effect of 16p11.2 CNVs on obesity if they do not lead 
to changes in disinhibited eating. The total natural indirect effect represents the effect of 16p11.2 CNVs 
on obesity attributable to 16p11.2 genotype-induced changes in feeding behavior. I used bootstrapping 
[107] to estimate the indirect and direct effects. This non-parametric approach estimates and generates 
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confidence intervals for the indirect effect by repeatedly (1000x) sampling with replacement from empirical 
approximations of the data. 
All analyses were conducted using SAS 9.4 (SAS Institute, Cary, NC, USA). Statistical 
significance was set at p<0.05. For analyses with an EAH behavior set as the outcome variable, I used a 
Bonferroni-corrected alpha of 0.0125 (0.05/4) to correct for multiple comparisons after factor analyses 
identified four EAH subscales. 
3.4 Results 
3.4.1 Factor Analysis Results 
	
The factor analysis of 14-item parental reports of EAH in their children generated four factors: 
EAH due to negative affect (EAH negative), EAH due to external cues (EAH external), EAH due to 
fatigue/anxiety (EAH fatigue), and EAH due to boredom (EAH boredom) (Appendix A5.1 and A5.2). When 
the same analysis was repeated for parental self-reports of EAH, three factors similar to the ones above 
were found (EAH negative, EAH external, and EAH fatigue) (Appendix A5.3 and A5.4). In the factor 
analysis of parents’ responses to the 31-item Child Feeding Questionnaire I focused on the two factor 
patterns that directly corresponded to parental restriction and pressure to eat, in light of their previously 
reported associations with both disinhibited eating and BMI [101] (Appendix A5.5). Detailed descriptions 
of each factor analysis are provided in Appendix A4. 
3.4.2 Study Population 
	
The study population consisted of 102 individuals from 64 deletion families (64 deletion carriers 
and 38 non-carriers) and 43 individuals from 26 duplication families (29 duplication carriers and 14 non-
carriers) for whom parental reports of EAH behaviors were obtained. Non-carriers were comprised of 
deletion and duplication carriers’ siblings, half-siblings, and cousins who genetically tested negative for 
the 16p11.2 BP4-BP5 CNV. When I restricted to families with de novo 16p11.2 CNV carriers, the study 
sample was reduced to 73 individuals from 40 de novo deletion families and 12 individuals from 6 
duplication families. Non-carriers were deletion and duplication carriers’ siblings, half-siblings, and 
cousins who were tested and found to be negative for the 16p11.2 BP4-BP5 CNV (Figure 4). 
3.4.3 Descriptive Statistics 
	
Table III shows descriptive statistics for subjects in deletion and duplication families stratified by 
genotype. The mean age of study participants was 9.7±4.2 years, ranging from 35 months to 25 years, 
and over 91% of individuals were above age 5. The gender and age distributions were similar across all 
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groups. When I restricted to families with de novo 16p11.2 CNV carriers, the study sample was reduced 
to 73 individuals from 40 de novo deletion families and 12 individuals from 6 duplication families. The 
study population’s composition is similar to that in which the EAH questionnaire was first validated with 
respect to mean age (~14) and obesity status (~25-30%) [89]. 
In comparison with non-carrier relatives, deletion carriers were younger (p=0.046) and had 
significantly higher average BMI z-scores (p=0.001), lower average full-scale IQ (FSIQ) scores 
(p<0.0001) and higher average scores for EAH external (p=0.003) and EAH boredom (p=0.01), but not 
EAH fatigue (p=0.07) or EAH negative (p=0.52) (Table III). The results were similar and stronger among 
de novo deletion carriers. The sample of duplication families was too small to detect differences between 
carriers and non-carriers for all outcomes, except FSIQ. 
3.4.4 Replication of Known Associations Between 16p11.2 Deletion with Obesity 
	
I first examined the relationship between BMI with advancing age among deletion carriers. After 
age 5, deletion carriers’ age- and gender-specific BMI z-scores exhibited a consistent upward trend 
compared to those of the general population (Figure 5). In random intercept random slope linear mixed 
models, deletion carriers had significantly elevated BMI z-scores relative to non-carriers (Estimate=0.69 
[0.16,01.23], p=0.02), and the random slope was statistically significant (p=0.02), indicating that strength 
of this effect varied significantly across deletion families. The effect of the deletion on BMI was even 
stronger after restricting the analysis to de novo families (Estimate=1.21 [0.6,1.83], p=0.001) and also 
varied significantly across families (p=0.048) (Table IV). These results are consistent with a previous 
characterization of deletion families that comprise a subset of those in this study [35]. 
3.4.5 16p11.2 Deletion and EAH Behaviors 
	
I subsequently evaluated the relationships between 16p11.2 genotype and EAH behaviors (Table 
V), and in deletion families I found that the 16p11.2 deletion was a significant predictor of EAH external 
(Estimate=0.71 [0.27,1.14], p=0.003), and this effect varied significantly between families (p=0.04). This 
result was robust to a Bonferroni correction for multiple comparisons (alpha=0.0125). EAH boredom 
(p=0.14), EAH fatigue (p=0.13), and EAH negative (p=0.26) were not associated with the deletion. In de 
novo deletion families the results were similar, as the relationship between the deletion and EAH external 
remained significant (Estimate=0.74 [0.15,1.32], p=0.02), but EAH boredom was also marginally 
associated with the deletion (Estimate=0.48 [-0.02,0.98], p=0.07), and the effect of deletion on these 
behaviors varied significantly between families (p=0.03 for EAH external and p=0.02 for EAH boredom). 
However, the results in de novo families were not significant after correcting for multiple comparisons. 
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3.4.6 EAH Behaviors and BMI z-score 
	
Next I predicted BMI z-score using the 16p11.2 deletion as well as each EAH behavior, to explore 
whether any EAH behaviors were related to BMI irrespective of 16p11.2 genotype, which is a potential 
common antecedent of these variables given the results above (Table VI). Both EAH external 
(Estimate=0.48 [0.25,0.7], p=0.0003) and EAH boredom (Estimate=0.52 [0.27,0.76], p=0.0002) were 
positively associated with BMI z-score in these models, while associations for EAH fatigue (p=0.17) and 
EAH negative (p=0.26) were not significant. In de novo deletion families EAH external (Estimate=0.55 
[0.32,0.78], p=0.0001) and EAH boredom (Estimate=0.51 [0.25,0.78], p=0.001) remained significant 
associated with BMI, and additionally BMI was associated with EAH fatigue (Estimate=0.32 [0.05,0.6], 
p=0.03) and nominally associated with EAH negative (Estimate=0.23 [0,0.46], p=0.07). 
3.4.7 Potential Confounders of the EAH-BMI Relationship 
	
Autism has been previously associated with 16p11.2 genotype [108, 109] and obesity [110], and 
in this population ASD was present in 23.7% of CNV carriers (16/64 deletion carriers and 6/29 duplication 
carriers), and one non-carrier from a duplication family. ASD could confound the relationships between 
EAH behaviors and BMI if it is associated with both, independent of the 16p11.2 CNV. However, in this 
study population, BMI was not associated with ASD across all family types (Appendix A6). 
I considered adjusting for confounding of the EAH-BMI relationships by restriction or pressure to 
eat, two parental feeding practices that were previously associated with both disinhibited eating and BMI 
[101] and were also associated with both EAH and BMI z-score in random intercept models (Appendix 
A7.1 and A7.2). However, both EAH and BMI z-score were both positively associated with parental 
restriction and negatively associated with pressure to eat, suggesting that the two parental feeding 
practices were consequences of EAH and BMI. Since neither parental feeding practice appeared to be a 
common antecedent of both EAH and BMI z-score, these variables did not confound the EAH-BMI 
relationship (Figure 6).  
EAH behaviors in parents themselves were also potential confounders of the EAH-BMI 
relationships in children but neither maternal nor paternal self-reports of EAH were associated with 
children’s BMI in deletion or de novo deletion families (Appendix A8.1-8.4). 
3.4.8 16p11.2 Genotype-Related Cognitive Deficits and EAH Behaviors 
	
 I evaluated the possibility that the identified connections between the 16p11.2 deletion and EAH 
behaviors could be distorted by deficits in cognitive functioning attributable to 16p11.2 genotype [33, 35, 
111] (Appendix A9.1). While I observed negative associations between FSIQ and EAH behavior scores 
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(Appendix A9.2), these relationships were confounded by the 16p11.2 deletion’s associations with EAH 
behaviors and FSIQ: the EAH-FSIQ associations were abolished after conditioning EAH subscale scores 
on the effects of both FSIQ and deletion (Appendix A9.3). 
3.4.9 Mediation Analysis of 16p11.2 Deletion, EAH Behaviors, and BMI z-score 
	
Having identified significant relationships between 16p11.2 deletion and BMI, 16p11.2 deletion 
and EAH external, as well as EAH external and EAH boredom with BMI, and ruled out potential 
confounders, I performed mediation analyses to quantify the pure natural direct and total natural indirect 
effects (via EAH behaviors) of 16p11.2 deletions on BMI (Table VII). In deletion families, the deletion led 
to an average 0.23 increase in EAH external score, which explained 36.6% of the total effect of the 
16p11.2 deletion on BMI in deletion families. The deletion did not have a significant direct effect on BMI 
that was independent of EAH external (p=0.78). Additional mediation analyses showed that the other 
EAH behaviors (EAH boredom, EAH fatigue, and EAH negative) did not mediate the effect of the 16p11.2 
deletion on BMI. This was expected given the lack of significant associations between the deletion and 
these three EAH behaviors. I repeated the mediation analyses in de novo deletion families, and again 
found a significant indirect effect of the 16p11.2 deletion on BMI, through EAH external. De novo 
deletions led to a 0.36 increase in EAH external score on average, which explained 31.2% of the de novo 
CNV’s effect on BMI. As in deletion families, in the de novo deletion families the other three EAH 
behaviors did not mediate the effect of the deletion on BMI. 
Due to the cross-sectional nature of BMI and EAH behavior measurements, it was unclear 
whether EAH behaviors preceded or followed obesity in this study population. Therefore, I also conducted 
mediation analyses in which EAH behavior was modeled as the outcome, to explore the degree to which 
BMI explained the relationship between the 16p11.2 deletion and EAH behaviors (Table VIII). BMI was a 
nominally significant mediator of the deletion’s effect on EAH external (Estimate=0.18 [-0.04,0.4], p=0.10) 
and EAH boredom (Estimate=0.18 [-0.02,0.38], p=0.08) in deletion families, explaining approximately 
30% of these effects. In de novo deletion families BMI was a significant mediator of the deletion’s 
relationship with all EAH behaviors. In the analyses summarized in Table IV there was only a strong 
association between the 16p11.2 deletion and EAH external, and based on the mediation analysis 67.9% 
of this relationship may be due to and increases in BMI due to the deletion (Estimate=0.48 [0.12,0.84], 
p=0.01). 
3.4.10 Duplication Carriers 
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 I examined the relationships between 16p11.2 genotype, EAH behaviors, and BMI z-scores in 
duplication families and found no significant associations, possibly due to the small sample size (Table IV, 
Appendix A10.1, A10.2, and A11). In an effort to increase statistical power to detect an effect of the 
duplication on BMI, I combined data from the deletion and duplication families, and modeled genotype as 
a 3-level variable (level 1: 3 copies; level 2: 2 copies; level 3: 1 copy) (Appendix A10.3). While the 
decreased p-value when modeling BMI as a function of the three CNV states together indicated an 
improvement in power to detect a difference between duplication carriers and non-carriers, this effect still 
did not reach statistical significance, although the test for trend was significant (p=0.005). As duplications 
were not significantly associated with BMI, I did not conduct mediation analyses using this combined 
dataset. 
3.4.11 Loss of Control (LOC) Eating 
	
 I also considered relationships between loss of control (LOC) eating and 16p11.2 genotype in 
deletion families, but only a single participant, a 12-year-old 16p11.2 deletion carrier, met full criteria for 
self-reported LOC eating. 
3.5 Discussion 
	
 Emerging evidence suggests that disinhibited eating behaviors may be heritable, play a role in 
excessive weight gain, and are highly prevalent in children [83]. They therefore represent potential 
mechanistic links between genetic susceptibility and obesity, as well as important targets for intervention. 
In this study I examined eating in the absence of hunger (EAH) behaviors in a genetically well-defined 
population, in which obesity is associated with 16p11.2 genotype. In addition, my analyses of 16p11.2 
CNV carriers’ relatives using mixed models permitted adjustment for obesity-related familial factors 
unrelated to the deletion and duplication. Parental reports of EAH behavior in children were analyzed due 
to their good correspondence with laboratory assessments and to avoid underreporting, especially among 
obese children.  
Figure 6 summarizes the associations identified in this study. I first confirmed that the 16p11.2 
deletion is significantly associated with obesity, consistent with previous work [29, 33, 35, 40]. The effect 
of the 16p11.2 deletion on obesity varied among families, and was strongest in families with de novo 
deletion carriers. This result was expected as the study population overlaps with that of a previous study 
replicating the positive deletion-BMI association [35]. I identified strong associations between BMI with 
EAH due to external triggers as well as EAH due to boredom in deletion families, and an additional 
association with EAH due to fatigue or anxiety in de novo families. I ruled out potential confounding of the 
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EAH-BMI relationship by parental feeding practices by inferring the direction of these relationships based 
on their signs. Parents’ EAH behavior and autism in children were also ruled out as child EAH-BMI 
confounders since neither was significantly associated with child BMI. 
My principal finding is that EAH attributable to external cues of good tasting food or because 
others are still eating explains over 30% of the 16p11.2 deletion’s strong positive association with obesity. 
The CNV did not have a significant indirect effect on BMI through EAH due to boredom, fatigue or anxiety, 
or negative affect. I ruled out any influence of children’s 16p11.2 genotype-related cognitive functioning 
deficits on EAH behavior, as children’s full-scale intelligence quotient (FSIQ) scores and EAH behavior 
scores were only associated through their independent associations with the 16p11.2 deletion. CNV-
transmitting parents’ cognitive functioning was normal and did not lead to biased reports of their children’s 
EAH behaviors, as neither maternal nor paternal FSIQ was significantly associated with EAH behaviors 
among children who inherited their CNVs (data not shown). In a second exploratory analysis with BMI 
modeled as a potential mediator, I found that 16p11.2 deletion-related increases in BMI might affect all 
measured EAH behaviors. In my initial analyses only EAH external was significantly associated with the 
deletion, and 61% of this relationship may be attributable to obesity. Lastly only one subject met full 
criteria for self-reported LOC eating, and only a small number of subjects fulfilled partial criteria for LOC 
eating, indicating that the 16p11.2 deletion is not related to this form of disinhibited eating. 
A limitation of this study is the method of ascertainment that was biased toward the selection of 
probands who were clinically symptomatic and prompted their parents or healthcare providers to seek a 
genetic diagnosis. However, the spectrum of neuropsychiatric phenotypes observed in this study’s 
16p11.2 deletion carriers was similar to that of 16p11.2 deletion carriers in a population-based 
ascertainment in Iceland, so the selection bias for deletion carriers is likely limited [112]. In addition, 
cascade genetic testing in the family identified carrier relatives, who contributed to the group of 16p11.2 
CNV carriers. Moreover, the non-carrier relatives were matched to carriers by familial factors and arose 
from the same source population. Furthermore, the lack of similar findings in the duplication carriers 
ascertained by the same method suggests that there is specificity of these findings to the deletion 
carriers. Another limitation is that the cross-sectional nature of the EAH behavior and growth 
measurements precluded inference of causal relationships between these variables, but this will be 
addressed with collection of longitudinal data. Without multiple concurrent prospective measures of both 
eating behaviors and growth parameters, it is unclear whether the disinhibited eating behaviors precede 
or follow obesity. 
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In summary, EAH due to external cues is a statistically significant mediator of the association 
between the 16p11.2 deletion and obesity, accounting for over 30% of this relationship. There is also 
quantitative evidence to suggest that increases in BMI due to the deletion lead to EAH external, 
potentially creating a positive feedback loop. These findings were independent of parental feeding 
practices and self-reported EAH behavior, not associated with 16p11.2 CNV-related cognitive defects or 
autism diagnoses, and robust to correction for multiple comparisons as well as the exclusion of study 
participants who inherited their deletions. My findings may eventually aid in isolating the specific gene(s) 
or regulatory element(s) in the 16p11.2 BP4-BP5 interval responsible for obesity-related phenotypes.  
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Background: SNPs in the first intron of the Fat Mass and Obesity-Associated (FTO) gene represent the 
strongest genome-wide associations with obesity, but their direct relevance to pathophysiology is unclear. 
In European populations, which have been the focus of most GWAS conducted to date, the SNPs are 
indistinguishable due to the high level of linkage disequilibrium (LD). On the other hand, in African 
Americans (AA) populations, reduced linkage disequilibrium and increased haplotype diversity permit 
more refined investigations to elucidate the SNP(s) directly relevant to obesity.  
Methods: In this study, I employed haplotype analyses of individual-level data from 5,643 unrelated AAs 
from the Atherosclerosis Risk in Communities Cohort (ARIC) and Women’s Health Initiative (WHI) study, 
as well as statistical fine-mapping using summary statistics from a study of FTO on over 20,000 AAs and 
over 1000 functional annotations from the Encyclopedia of Non-coding Elements (ENCODE) and 
Roadmap Epigenomics projects, with the goal of identifying FTO SNP(s) that are truly associated with 
obesity. 
Results: The haplotype analyses suggest that at least two distinct signals underlie the FTO-obesity signal. 
Statistical fine mapping showed that two SNPs have the highest posterior probability of association with 
obesity: rs9927317, and rs62033405. These markers overlapped with significant EnhAc (possible 
enhancer attributable to H3K27ac marks) and Tx5 regions (preferentially associated with the 5’ ends of 
transcribed genes) in the substantia nigra brain region, chondrocytes, as well as white adipocytes. 
Conclusions: I found two distinct SNPs with the highest probability of direct association with obesity as 
well as highly plausible contexts in which these variants may contribute to the pathogenesis of obesity, 
particularly the substantia nigra region of the brain, in which FTO genotype has been shown to affect 






Genome-wide association studies (GWAS) of obesity in people of European, African, and East 
Asian descent have systematically interrogated common variants, identifying ~75 genome-wide significant 
associations [42, 43, 56, 113-115]. The mechanisms underlying the majority of these associations are 
unclear, as most obesity-associated single nucleotide polymorphisms (SNPs) do not lie near or within 
genes previously implicated in monogenic forms of the disease. In addition, GWAS-identified SNPs can 
be in linkage disequilibrium (LD) with numerous variants that have indistinguishable associations with 
disease. The most striking example is the Fat Mass and Obesity-Associated (FTO) gene, as the strongest 
and most robustly replicated SNPs associated with obesity lie in the first intron of FTO [41], but their direct 
relationship with the disease has not been fully elucidated. 
FTO encodes an ortholog to the AlkB family of enzymes that demethylate nucleic acids, and 
manipulation of rodent Fto expression leads to directionally inconsistent changes in body weight [116-
119]. The first intronic region of FTO is also near the transcriptional start site of the gene Retinitis 
Pigmentosa GTPase Regulator-Interacting Protein-1 Like (RPGRIP1L), a ciliary gene that is coded in the 
5’ direction. Ciliary dysfunction may be related to the pathogenesis of obesity, as it features prominently in 
the ciliopathies Bardet-Biedl and Alström syndrome [120, 121]. Consistent with this notion, mice 
hypomorphic for Rpgrip1l have increased adiposity, hyperphagia, and diminished response of food intake 
to leptin administration [122]. 
Obesity-associated FTO SNPs have similar effects on BMI in European-ancestry and African-
ancestry populations, such as African Americans (AAs), with each minor allele increasing BMI by 0.39 
kg/m2 and 0.41 kg/m2 respectively. However, these SNPs explain more BMI variance in Europeans 
(0.34%) than AAs (0.10%), likely due in part to higher minor allele frequencies in Europeans (~43%) 
compared to AAs (~12%) [42, 43] as well as the higher prevalence of obesity in AAs [123]. 
Interestingly, the FTO SNPs associated with obesity in Europeans and AAs are mutually 
exclusive [41]. While both groups of SNPs are in LD among Europeans, in AAs each group of SNPs 
belongs to an independent LD cluster (Table I). These LD patterns can be explained by the two groups’ 
distinct population genetic histories. AAs represent an admixture of previously isolated Africans, 
Europeans, and other groups due to the transatlantic slave trade and its historical and social sequelae in 
the United States. Africans are the oldest of modern human populations in evolutionary terms, and have 
experienced more generations for LD to decay via recombination and mutation, compared to other 
ancestral groups [45, 124]. As a consequence of reduced LD, in GWAS of AAs fewer SNPs may tag 
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pathologic loci and disease-associated SNPs may reside closer to disease-causing alleles, compared to 
GWAS of relatively younger populations such as Europeans and Asians.  
Due to population admixture, AAs’ chromosomes also represent a mosaic of chromosomal blocks 
from distinct ancestral subpopulations [46]. In contrast, European genomes have undergone less 
recombination and arose from ancient bottlenecks associated with Out-of-Africa migrations, and therefore 
have higher levels of LD, low haplotype diversity, and low levels of population structure (population 
stratification and hidden relatedness) [47-53, 124]. 
Previous work suggests that the transcription factor Cut-like Homeobox 1 (CUX1) may play an 
important role in regulating the expression of FTO and/or RPGRIP1L. Preliminary analyses revealed that 
the apparent ancestry-specific LD clusters of obesity-associated FTO SNPs each tag distinct SNPs within 
putative CUX1 binding sites: rs8050136 in Europeans and rs1421085 in AAs (Figure 7). rs8050136 is 
associated with obesity in individuals of European ancestry and lies within a CUX1 binding site. Its risk (A) 
allele decreases the binding affinity of the short (p110) CUX1 isoform, a transcriptional activator of FTO 
and RPGRIP1L [125]. The risk (C) allele at rs1421085 is predicted to disrupt binding of CUX1 [74], and 
was also recently shown to disrupt binding of the ARID5B repressor, resulting in increased Iroquois 
Homeobox 3 and 5 (IRX3 and IRX5) expression in pre-adipocytes and consequent reduced mitochondrial 
thermogenesis as well as increased lipid storage [126]. 
The disparity between European and AA FTO-obesity associations may therefore be driven by 
ancestry-specific haplotypes containing distinct functional SNPs. Using individual-level data from 5,463 
unrelated AAs from extant population studies, I phased SNPs previously associated with obesity in AAs 
(rs1421085, rs3751812, and rs17817964), Europeans (rs8050136 and rs9939609), and both groups 
(rs1558902 and rs9930506), identified the risk haplotype(s), and performed stratified analyses to 
determine which SNP(s) explain the risk haplotype(s)’ associations with obesity. Next, I distinguished 
FTO SNPs in LD by statistically fine-mapping their summary association statistics from a study of FTO 
and obesity in over 20,000 AAs [74], while incorporating LD data from the 1000 Genomes Project as well 
as functional annotations from the Encyclopedia of Non-coding Elements (ENCODE) [127] and Roadmap 
Epigenomics [128] Projects, with the goal of identifying FTO SNP(s) that are truly associated with obesity. 
4.3 Methods 
4.3.1 Individual-level Data 
	
The Population Architecture using Genomics and Epidemiology (PAGE) study comprises large, 
ethnically diverse, and well-characterized extant population studies, with subjects ranging from middle 
age to old adulthood [129]. From the Database of Genotypes and Phenotypes (dbGaP), I obtained 
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access to Illumina Metabochip SNP data from 5,463 self-reported African Americans who were genotyped 
as part of the PAGE Metabochip Pilot Study: 3,335 individuals from the Atherosclerosis Risk in 
Communities (ARIC) study and 2,128 women from the Women’s Health Initiative (WHI) (Table IX.A). 
4.3.2 Summary Statistics 
	
 In addition to individual-level genotypic data, I obtained summary association statistics (Z-scores) 
from the largest study of FTO and obesity in AAs to date [74], involving a meta-analysis of data from over 
20,000 AAs genotyped on the Metabochip by the PAGE consortium: 3,297 ARIC study participants, 5,312 
women from the WHI, as well as AAs from the Multiethnic Cohort (MEC) (N=3,865), the Hypertension 
Genetic Epidemiology Network (HyerGEN) (N=1,171), and GenNet (N=517). Metabochip SNPs were 
imputed for an additional 6,326 women genotyped by the WHI SNP Health Association Resource 
(SHARe) on the Affymetrix 6.0 array [130] and also included in the analysis. Further details regarding 
each source population are in Appendix A12 as well as the reports by Peters et al. and Gong et al. [56, 
74]. 
Summary association data are available for a total of 51 FTO SNPs: all 7 SNPs to be analyzed in 
the haplotype association analyses, the 4 SNPs most significantly associated with obesity in the meta-
analysis of AAs (rs56137030, rs62033400, rs7188250, and rs62033413), 3 other FTO SNPs that were 
associated with obesity in previous GWAS of Europeans (rs1121980, rs6499640, and rs9941349), thirty 
rs56137030 tag SNPs at the FTO locus (21 with r2 >0.5 and 9 with r2 >0.2 to <0.5 in AAs), and 7 SNPs 
highlighted in previous studies of AAs (Appendix A13). For some SNPs the authors switched the 
reference and alternate alleles, designating the non-reference allele as the “coding allele.” The Z-scores 
for these markers were corrected by multiplying by -1 and the allele frequencies were checked for 
comparability with those in 1000 Genomes African Southwest (ASW), representing AAs, before the 
summary statistics were used for subsequent analyses. 
4.3.3 Genotyping 
	
 Samples were genotyped on the Metabochip at the Human Genetics Center of the University of 
Texas-Houston (ARIC GenNet and HyperGEN), the University of Southern California Epigenome Center 
(MEC), and the Translational Genomics Research Institute (WHI) [131]. Blinded duplicates and intra-





 The Metabochip [131] is a custom Illumina Infinium iSelect genotyping array containing 196,725 
SNPs designed to replicate and fine-map GWAS-identified regions for 23 metabolic traits and diseases. 
SNPs were selected based on data from the International HapMap Project [132] and the August 2009 
release of the 1000 Genomes [103] Project, and include polymorphisms associated with 11 primary 
metabolic and atherosclerotic-cardiovascular traits (Tier 1: type 2 diabetes [T2D], fasting glucose, 
myocardial infarction, coronary artery disease, LDL-cholesterol, HDL-cholesterol, triglycerides, BMI, 
waist-to-hip ratio, systolic and diastolic blood pressure, and QT-interval), 12 secondary metabolic and 
atherosclerotic-cardiovascular traits (Tier 2: fasting insulin, 2h glucose, HbA1c, T2D age of diagnosis, 
early onset T2D, waist circumference adjusted for BMI, height, percent fat mass, total cholesterol, platelet 
counts, mean platelet volume, and white blood cell counts), as well as SNPs with any validated (genome-
wide significant) association to any human trait (as of December 2008), along with a proxy to guard 
against genotyping failure (r2>0.9 with original SNP) (Tier 3). One-third of the SNPs are replication 
targets, while 62% are in fine-mapping regions. The remaining 5% of polymorphisms are copy-number 
polymorphism (CNP), tag SNPs, sex chromosome markers, major histocompatibility complex (MHC) 
SNPs, mitochondrial DNA SNPs, and fingerprint SNPs for sample tracking [133]. Details regarding SNP 
calling and quality control are available in Appendix A14 and were previously described [56, 74]. 
4.3.4 Outcome Definition 
	
The primary outcome for both haplotype association and statistical fine-mapping analyses was 
ln(BMI). Since the distribution of BMI is right-skewed, log-transformation was used to reduce the influence 
of outliers on the analyses. Waist-hip-ratio (WHR) was available for both the ARIC and WHI datasets, and 
the phasing and haplotype association analyses were repeated using WHR to corroborate results with 
ln(BMI) set as the outcome. 
4.3.5 Confounding by Ancestry 
	
Population stratification due to admixture arises when a population comprises subpopulations 
with unique demographic histories, and consequently distinct disease and allele frequencies. Systematic 
differences in cases’ and controls’ allele frequencies due to ancestry rather than disease status 
represents a source of dependence that could confound associations between genotype and phenotype 
[78-80]. I adjusted for population stratification as a covariate using principal components analysis (PCA). 
To account for possible heterogeneity arising from differential admixture in AAs, I used the ADMIXTURE 
program [134] to generate ancestry proportions in a supervised analysis, using 90 HapMap YRI and 165 
CEU subjects as proxies for ancestral African and European populations, and examined whether the 
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phasing and allelic association analysis results differed between AAs who shared relatively more (i.e. 
>=60%) or less (<60%) markers with the YRI trios. This cutoff was based on the observation that over 
90% of the ARIC cohort and over 85% of the WHI cohort shared >=60% markers with YRI trios (Appendix 
A15). 
4.3.6 Functional SNP Annotations 
	
The ENCODE project annotated more than 80% of the human genome with functional elements 
including sites of Deoxyribonuclease I (DNase I) hypersensitivity (DHSs), transcription factor binding, and 
histone modification [127]. In addition the NIH Roadmap Epigenomics Consortium generated reference 
epigenomic maps for “normal” human cells and tissues, using RNA-seq, DNase, DNA methylation, and 
histone modification data [128] (Appendix A16). The Roadmap reference epigenomes’ full names and 
additional information are in Appendix A17. 
4.3.7 Analytic Approaches 
	
4.3.7A) Haplotype Analyses of Individual-Level ARIC and WHI Data 
Principal Components Analysis (PCA) 
 Using PLINK software 1.90 [135], I inferred orthogonal principal components (PCs) of ancestry 
representing the top eigenvectors of the standardized similarity matrix between samples. I used a scree 
plot to select the number of PCs based on the rate of change in eigenvalue magnitudes for each 
component. The top PCs’ eigenvectors were used as covariates in subsequent analyses to correct for 
population stratification. The genomic control variance inflation factor (λGC) was used to show whether 
population stratification was inflating the genotype-disease test statistic. To generate λGC values, I 
performed genome-wide SNP association analysis of ln(BMI) and WHR, with and without adjusting for 
ancestry. A post-adjustment λGC value near unity (<1.05) [136] and significant p- values for obesity-
associated SNPs confirmed that the PCs adequately accounted for population stratification. 
Haplotype Phasing and Association Testing 
 I phased haplotypes composed of the FTO-associated SNPs rs1421085, rs1558902, rs8050136, 
rs3751812, rs9939609, rs17817964, and rs9930506 using and PLINK 1.07 [137]. Given the genotypes of 
unrelated individuals and assuming the data were in Hardy-Weinberg equilibrium, the program used an 
expectation-maximization (EM) algorithm to estimate haplotypes and their frequencies [138, 139]. For 
each study population, I used PLINK to estimate haplotype frequencies with the minimum haplotype 
frequency threshold set to 1%. Next, setting ln(BMI) or WHR as the outcome and adjusting for age, 
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gender (for the ARIC study), and ancestry, I performed a global haplotype association test using a χ2 test 
with n-1 degrees of freedom, where n was the number of haplotypes identified in the prior phasing step. 
Since I expected rs1421085 (and SNPs in LD) to drive any haplotypic association(s) between FTO and 
obesity in AAs, I tested whether the haplotype(s) containing the rs1421085 alternate allele were 
associated with obesity while designating the other haplotypes to the reference haplogroup. Each dataset 
was analyzed separately due to inter-study heterogeneity. 
Stratified Haplotype Analyses 
I also separately phased FTO SNPs associated with obesity in African populations (rs1421085, 
rs1558902, rs3751812, and rs17817964) and in Europeans but not African ancestry groups (rs8050136 
and rs9939609) using PHASE 2.1 [140, 141], and examined average BMI and WHR values for each 
haplotype as well as all combinations of ‘African’ and ‘European’ haplotypes. As the IRX3 eQTL 
rs9930506 is not in strong LD with the other FTO SNPs, I phased this SNP in additional analyses of both 
AA and European haplotypes. rs9939506 is associated with obesity in Europeans [77] and was 
significantly associated with obesity (p=3.9x10-5) in AAs when a set of candidate genes were studied 
(p=5.8x10-5 significance threshold) but not after Metabochip-wide correction for multiple comparisons 
(p=2.5x10-7 significance threshold) [56]. 
4.3.7B) Statistical Fine-Mapping of Summary Association Statistics from PAGE Meta-GWAS 
Previous Meta Analysis by Peters et al. 
In each dataset, the PAGE consortium previously performed association studies on Metabochip 
FTO SNPs with ln(BMI) as the outcome in linear regression models assuming additivity. Covariates 
included continuous age, study site, the top two principal components of ancestry, as well as a sex and a 
sex*age interaction term for all studies except the WHI [74]. Linear mixed models were used to account 
for relatedness in family data from the GenNet and HyperGEN studies. METAL [142] was used to perform 
a fixed-effects meta-analysis with inverse variance weighting. Q-statistics and I2 were used to quantify 
heterogeneity across studies. 
Statistical Fine-Mapping Analyses 
The statistical fine-mapping program PAINTOR takes as input (1) the Z-score or Wald statistic 
( "#$ " ) from regressing ln(BMI) on each SNP, (2) an LD matrix representing pairwise Pearson correlation 
coefficients between each SNP, and (3) an annotation matrix with rows corresponding to SNPs and 
columns representing unique annotations (i.e. SNP i is a member of annotation K if entry [i,k] = 1). I 
created an LD matrix using data from the 1000 Genomes ASW population, and generated a 51×1,145 
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annotation matrix for all 51 FTO SNPs with summary statistics and LD data available. Functional 
annotations included DHS data from Maurano et al. [143] and Thurman et al. [144] as well as chromatin 
states from Hoffman et al [145] and the Roadmap Epigenomics Consortium [128]. 
 The prior probability of association for each SNP was governed by its membership in tissue-
specific functional annotations. To determine which annotations were directly relevant to the truly causal 
subset of obesity-associated SNPs, I used an empirical Bayes approach [146, 147]. I fit a PAINTOR 
model for each annotation independently to generate annotation-specific marginal log likelihoods, then 
divided each value by the marginal likelihood for the null model (no annotations) to compute a likelihood 
ratio statistic (~χ2 with 1 d.f.). I included the most statistically significant (p<0.10) annotations in a final 
PAINTOR model to calculate each SNP’s posterior probability of association with obesity. As additional 
input, PAINTOR required specification of the number of SNPs were truly “causal” (driving the association 
signal at the FTO locus), and I based this specification on the number of unique signals identified from 
haplotype analyses. 
4.4 Results 
4.4.1 Principal Components Analysis 
	
I adjusted for confounding by population stratification using all autosomal Metabochip SNPs 
outside of the 2.5-kb flanking the FTO and RPGRIP1L genes, to avoid controlling for the effect of interest. 
After pruning the marker list to exclude SNPs in strong pairwise LD (r2>0.3) as well as common variants 
(minor allele frequency >0.05), 69,209 markers remained; well above the ~10,000 SNPs needed to 
accurately infer population structure [148, 149]. Without any adjustment for population stratification, the 
variance inflation (λGC) for the association between rs1421085 and lnBMI in ARIC was 1.19, and after 
adjustment for the top 3 principal components the λGC was negligible (1.04). 
4.4.2 Haplotype Phasing Association Testing and Stratified Analyses 
	
 I used individual-level genotypic and phenotypic data to perform phasing, identify the risk 
haplotype(s), and determine the minimum number of signals that may underlie these haplotype(s)’ 
relationship(s) with obesity. At present Metabochip data is available for all 3,335 AAs from the 
Atherosclerosis Risk in Communities (ARIC) study and 2,128 of 5,312 (40%) of women from the Women’s 
Health Initiative (WHI) (Table IX.A). Interestingly, over ~75% of subjects from the currently available WHI 
data were obese, compared to ~50% in the entire population of WHI AAs genotyped by PAGE. The 
remaining 3,184 WHI AAs without SNP data available were also ~50% obese (data not shown). The 
2,128 WHI subjects described above may therefore represent the more severely obese AA women from 
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the WHI study (Table IX.B). 
Phasing the FTO SNPs rs1421085, rs1558902, rs8050136, rs9939609, rs3751812, rs17817964, 
and rs9930506 yielded 6 haplotypes with similar frequencies in both the ARIC and WHI cohorts (Table 
X.A). A significant omnibus association result rejected the null hypothesis that all haplotypes had 
equivalent effects on obesity. CTATTTG was designated the risk haplotype since it was the only 
haplotype containing the obesity-associated (C) allele for rs1421085, as well as the risk alleles of several 
other obesity-associated SNPs from studies of AAs (rs1558902, rs3751812, and rs17817964).  
Mean BMI was slightly elevated for CTATTTG carriers, compared to non-carriers, in both the 
ARIC and WHI studies, while mean WHR was similar across haplotypes (Table X.B). The CTATTTG 
haplotype was nominally associated with ln(BMI) in the full ARIC cohort (F=3.68; p=0.055), and the 
association became significant (F=4.65; p=0.031) after restricting to ARIC subjects sharing over 60% 
markers with the YRI trios from the HapMap Project (Table X.C), but not those sharing >70% or >80% of 
their markers with the Yorubans. Stratification by gender showed that the association was driven by ARIC 
females (F=3.88; p=0.049), as the haplotype was not significantly associated with ln(BMI) in ARIC males 
(F=0.196; p=0.658). I found no association between the risk haplotype and ln(BMI) in the WHI cohort 
(F=0.023; p=0.88). In both the ARIC and WHI studies, waist-to-hip ratio (WHR) was not significantly 
associated with the CTATTTG haplotype. All analyses were adjusted for age, gender (for ARIC), as well 
as the top three principal components of ancestry. 
When the obesity-associated FTO SNPs from studies of AAs (Table XI.A) and Europeans (Table 
XI.B) were separately phased, in the ARIC data BMI was elevated among carriers of the African risk 
haplotype (CTCT) (Table XI.A.2). The same pattern was not observed for the European risk haplotype 
(AT) or in the WHI data, and variation in WHR across haplotypes was negligible (Tables XI.A and XI.B).  
I further considered BMI values for carriers of all European-and African- ancestry FTO haplotype 
combinations, with and without the inclusion of rs9930506 in the phasing. The European risk haplotype 
(AT) alone did not appear to elevate mean BMI beyond levels attributable to the risk alleles of SNPs 
significant in studies of AAs. However, the addition of the rs9930506 major (A) allele to the European risk 
haplotype (ATA/CTTT vs. ATG/CTTT) appeared to elevate BMI beyond the level due to the African risk 
haplotype CTTT (Table XI.C). Therefore, the above haplotype analyses suggest that there may be at 
least two distinct signals, from the CTTT haplotype and rs9930506, underlying the relationship between 
FTO and obesity. 
4.4.3 Statistical Fine-Mapping of the FTO Locus 
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 The haplotype analyses suggested that at least two distinct functional SNPs may contribute to the 
FTO-obesity association, but did not distinguish markers in strong LD. Therefore I carried out statistical 
fine-mapping assuming two causal SNPs, utilizing summary statistics for 51 FTO SNPs (Appendix A13) 
from a previous study of the FTO locus and obesity (Table IX.B) [74], LD data from the ASW population, 
as well as 1,145 functional annotations from ENCODE and Roadmap. 
First, I identified the tissue-specific functional annotations that were significant (p<0.10) in a 
PAINTOR model assuming four causal SNPs underlie the association signal at the FTO locus (Table XII). 
The SNPs overlapping with these annotations are presented in Appendix A18. In brief, annotations in 1) 
possible enhancers containing H3K27ac marks (EnhAc) as well as 2) regions positionally biased toward 
the 5’ end of actively transcribed genes (Tx5) were significant, in fat (E023), brain substantia nigra (E074), 
bone (E049), liver (E066). 
Using the significant annotations, I then generated a PAINTOR model of the posterior probability 
of association (PPA) for each SNP. The results are summarized in Table XIII, which also shows the 
significant annotations overlapping with the highest-ranking SNPs. rs9927317 and rs62033405 had the 
highest PPA (Figure 8). rs9927317 overlapped with significant Tx5 annotations in mesenchymal stem cell 
derived adipocyte cultured cells (E023), mesenchymal stem cell derived chondrocyte cultured cells 




FTO has the strongest association in obesity GWAS, but the direct disease relevance of the 
intron 1 SNPs driving this signal has not been elucidated. Capitalizing on the Metabochip’s locally high 
SNP density, AAs’ low LD and high haplotype diversity, and leveraging functional annotations in non-
coding DNA, I sought to determine the specific variants and tissues responsible for the relationship 
between FTO and obesity. I first performed haplotype analyses of individual-level data to determine the 
minimum number of signals underlying the association peak. Next I performed statistical fine-mapping to 
rank FTO SNPs by their posterior probability of association (PPA) with obesity, using summary statistics 
from a study of FTO in over 20,000 AAs, as well as functional annotations from the ENCODE and 
Roadmap Epigenomic consortia.  
Haplotype association analyses confirmed a significant relationship between the FTO haplotype 
containing previously established risk alleles (CAATTTG) with ln(BMI) in subjects from the ARIC study 
(p=0.031) but not those in the WHI study (p=0.528), the only all-female AA study genotyped by the PAGE 
consortium. Consistent with these results, in the study of FTO and obesity among AAs by Peters et al. the 
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association between ln(BMI) with rs1421085, as well as other FTO SNPs, was also weaker in the entire 
set of WHI subjects compared to the ARIC, GenNet, MEC, and HyperGen subjects [74]. Waist-to-hip ratio 
(WHR) was not associated with the risk haplotype in both studies. The lack of association between BMI 
and FTO in the WHI women with individual-level data available likely do not reflect aspects of body 
composition unique to women, as the significant association in the ARIC cohort was driven by female 
subjects. The 2,182 WHI subjects from the Metabochip Pilot study had higher obesity prevalence than all 
WHI subjects, but did not have lower variability in BMI compared to ARIC subjects. Therefore, other 
factors, possibly related to the ascertainment of the 2,182 WHI subjects may have affected power to 
detect an association between FTO and obesity. 
Haplotype analyses using the ARIC data showed that the African risk haplotype CTTT and the 
major (A) allele at rs9930506 were related to elevated mean BMI. The rs9930506 A-allele only co-
occurred with the CTTT haplotype in the presence of the European risk haplotype (AT). This allele has 
been associated with expression of IRX3 [150]. Therefore, two distinct variants (or their proxies) may 
drive the association between the FTO locus and obesity. 
 I next performed statistical fine mapping to distinguish FTO SNPs in LD by ranking them by their 
posterior probability of association (PPA) with obesity, as well as identify the tissue or cellular contexts in 
which these markers contribute to obesity pathophysiology. Based on earlier haplotype analyses, a two-
SNP model was the most appropriate, although additional distinct variants could plausibly contribute to 
the FTO-obesity relationship. In the model assuming two causal SNPs, rs9927317 and rs62033405 had 
the highest PPA. 
Summary statistics were available for rs9927317 because it is a weak proxy for the top BMI-
associated SNP rs56137030 (r2=0.23) in the study by Peters et al., and rs9927317 is not strongly 
correlated with any other SNPs with summary statistics made available by the authors. rs62033405 is 
correlated (r2>0.8) with obesity-associated FTO SNPs from studies in AAs, including rs1421085, 
rs1558902, rs3751812, and may underlie these SNPs’ previous associations with obesity. The second 
signal identified in the haplotype association analyses came from the IRX3 eQTL rs9930506, but this 
SNP’s signal was not represented among the high-PPA SNPs, as rs9927317 and rs62033405 were only 
weak proxies r2~0.25. However, in the study by Claussnitzer et al. genome editing of rs1421085, a proxy 
for rs9927317, modulated the expression of IRX3 [126], possibly accounting for the effect of rs9930506 or 
its proxies. 
rs9927317 was significantly enriched for Tx5 annotations in white adipocytes (E023), bone 
(E049), as well as brain tissue from the and substantia nigra (E074), while rs62033405 was enriched with 
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EnhAc sites in E023 and E049. Tx5 stands for “Transcribed – 5’ preferential,” meaning the annotated 
region is preferentially associated with the start end of actively transcribed genes. EnhAc stands for 
“Primary H3K27ac possible Enhancer,” meaning it is a possible enhancer site due to the presence of 
H3K27ac marks associated with the activation of enhancer and promoter regions. The genes with active 
transcription associated with these annotations is not clear but they could include FTO itself, and previous 
work suggests that one or more of the genes proximal to the first intron of FTO, including RPGRIP1L 
[122], IRX3 [126, 150], IRX5 [126], AAKTIP [151], and RBL2 [152], may contribute to the pathogenesis of 
obesity governed by regulatory variation in FTO intron 1. 
The substantia nigra is part of a dopamine signaling circuit that also includes the ventral 
tegmental area, caudate putamen, and nucleus accumbens. Fto-deficient mice had impaired dopamine 
type 2 and type 3 receptor (D2/3R)-dependent neuronal activation and behavioral responses [153] related 
to reward sensitivity and addiction, as well as locomotor activity. Claussnitzer et al. recently found that 
genome editing in pre-adipoctyes homozygous for the obesity risk allele at rs1421085 restored binding by 
ARID5B at this site and consequent repression of an enhancer of IRX3 and IRX5, permitting a shift from 
energy-storing white adipocytes to energy-burning brown adipocytes. These pre-adipocytes (E025) were 
distinct from the white adipocytes (E023) in which I identified significant EnhAc and Tx5 annotations for 
the high-PPA SNPs, and rs62033405 tags rs1421085. Lastly, EnhAc and Tx5 annotations overlapping 
with both rs9927317 and rs62033405 were also identified in chondrocytes. Among osteoarthritic patients, 
the chondrocytes of those with obesity are more responsive to leptin than patients who were non-obese 
[154]. In summary, this study sheds light on novel and highly plausible contexts in which non-coding FTO 
SNPs may contribute to obesity risk. 
Unmeasured lifestyle and environmental factors such as diet and exercise may modify the effect 
of FTO genotypes on obesity status. Moreover AAs have different body composition compared to 
European ancestry populations [155, 156] but more nuanced measures of adiposity, particularly fat mass 
as a percentage of total body weight, were only available for 10% of the WHI cohort and unavailable for 
the rest of the cohorts genotyped by the PAGE consortium. Lack of adjustment for these variables may 
have resulted in distorted associations between genotype and phenotype. 
The available ENCODE and Roadmap tissues and cells with annotations may not have been 
representative of pathophysiological contexts in which FTO/RPGRIP1L affect energy, but over a thousand 
annotations were analyzed in this study. I identified tissues with biologically plausible roles in obesity 
pathophysiology, particularly brain tissue from the substantia nigra. Moreover, while summary statistics 
for a reasonably large number of SNPs were available for statistical fine-mapping analyses, the truly 
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disease-relevant markers may not have been analyzed in this study, and may only be identified through 
analyses of higher-resolution genetic data. In the future as more functional annotation and association 
data from larger samples are made available, analyses similar to those I report here have great potential 
to further refine association signals such as that from the FTO locus in obesity GWAS. 
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Chapter 5: Conclusion 
 The goal of my thesis was to characterize the pathophysiological relevance of obesity genes 
outside the leptin-melanocortin receptor pathway, given that defects in this pathway are quite rare and 
often untreatable, limiting their direct applicability as targets for therapeutic interventions. I focused on the 
16p11.2 BP4-BP5 deletion and SNPs in first intron of the Fat Mass and Obesity-Associated (FTO) gene; 
both have consistent but unclear direct relationships with obesity. Prior studies had not investigated the 
mechanisms underlying the relatively novel 16p11.2-BMI relationship. FTO and its proximal genes have 
been subject to intense study, but few studies have systematically examined the functional consequences 
of the intronic SNPs driving the FTO-obesity association. 
 To study the 16p11.2 CNV, I employed linear mixed models and formal mediation analyses using 
a genetically well-defined group of families with likely shared disease mechanisms, to identify disinhibited 
eating behaviors that may explain the 16p11.2 genotype-BMI relationship. I found that 30% of the 
16p11.2 deletion’s strong positive association with BMI was attributable to eating in the absence of 
hunger due to external cues of good tasting food or because others are still eating (EAH external). This 
result was specific to EAH external, unrelated of IQ deficits or autism associated with the deletion, 
independent of parents’ own EAH behavior and child feeding practices, and robust to correction for 
multiple comparisons as well as restriction to de novo deletion carriers. While longitudinal studies are 
needed to establish the temporal order of EAH behavior and increased BMI among deletion carriers, the 
identification of EAH external as a potential mediator of the deletion’s effect on adiposity could aid in the 
identification of the pathophysiologically relevant 16p11.2 genes or regulatory features. 
 I characterized the FTO locus in African Americans (AAs), as obesity-associated SNPs from this 
population should be closer the truly disease-related markers as a result of this population’s reduced LD 
and increased haplotype diversity. Leveraging non-coding DNA functional annotations from the ENCODE 
and Roadmap Epigenomic projects, I performed statistical fine-mapping to identify and prioritize 51 SNPs 
with summary association statistics available, and identified two SNPs with the highest posterior 
probability of association with obesity: rs9927317 and rs62033405. In brain substantia nigra, 
chondrocytes in bone, as well as white adipocytes, the two markers were enriched for Tx5 regions 
associated with the 5’ ends of actively transcribed genes, as well as EnhAc annotations suggestive of 
enhancer sites. rs62033405 may underlie previous association signals from rs1421085 in AAs and 
rs1558902 in Europeans and AAs. The functional relevance of rs9927317 has not been well 
characterized. The identification of novel tissues that may be pathophysiologically relevant is promising, 
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particularly the substantia nigra, which is part of the dopamine signaling circuit related to addiction and 
reward. 
 In summary, my thesis work applied mediation analysis and statistical fine-mapping leveraging 
functional annotations to clarify genes with unclear associations with obesity. The results provide proof-of 
principle of methods to mechanistically dissect genotype-phenotype relationships for discrete and highly 
penetrant genetic risk factors such as the 16p11.2 CNV, as well as the power of leveraging both 





Table I: Linkage disequilibrium (r2) between obesity-associated FTO SNPs in the 1000 Genomes African 






SNP AA SNP Eur SNP AA SNP IRX3 eQTL 
  rs1421085 rs1558902 rs8050136 rs3751812 rs9939609 rs17817964 rs9930506 
AA CUX1 SNP rs1421085 -       
 rs1558902 0.972 -      
Eur CUX1 SNP rs8050136 0.138 0.136 -     
AA SNP rs3751812 0.966 0.939 0.147 -    
Eur SNP rs9939609 0.117 0.116 0.841 0.125 -   
AA SNP rs17817964 0.908 0.883 0.151 0.934 0.127 -  
IRX3 eQTL rs9930506 0.420 0.400 0.090 0.430 0.070 0.460 - 
Blue SNPs are associated with obesity in Europeans. Red SNPs are associated with obesity in African 




Table II: Summary of FTO-obesity association patterns from studies of obesity in African-ancestry 
populations 
 
Studies with problematic adjustments for ancestry (further details are provided in the text) are highlighted 
in yellow. Underpowered studies are marked with red text. Underpowered but notable studies are 
highlighted in blue. Well-powered studies with appropriate adjustments for ancestry and high coverage of 
FTO SNPs are marked with blue text. 
Association results for FTO SNPs robustly associated with obesity in Europeans (green), Africans (red), 
or both (black) are shown for each study (1=associated, 0=not associated, ~=marginal association). 
Abbreviations: AA (African American), EA (European American), Hisp (Hispanic), AAPI (Asian Americans 






Table III: EAH questionnaire respondents’ gender and mean age, BMI z-score, FSIQ, and EAH behavior scores by 16p11.2 genotype 
      EAH Behavior 
  






boredom EAH fatigue 
EAH 
negative 
N Males (%) Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD Mean ± SD 
All Deletion Families 
Carriers 64 34 (53.1%) 9.2±3.5* 1.2±1.2** 84.5±16.0*** 0.3±1.1** 0.3±0.9** 0.2±1.1 0.2±1.1 
Non-carriers 38 16 (42.1%) 10.6±4.7 0.4±0.9 107.6±10.2 -0.3±0.7 -0.3±0.6 -0.2±0.8 0±1.0 
De Novo Deletion Families  
Carriers 40 24 (60.0%) 9.1±3.7* 1.4±1.2*** 88.7±15.6*** 0.3±1.1** 0.4±1.0** 0.2±1.0 0.2±1.0 
Non-carriers 33 15 (45.5%) 10.9±4.9 0.3±0.9 107.3±10.1 -0.3±0.7 -0.3±0.6 -0.2±0.8 0±1.1 
Duplication Families 
Carriers 29 18 (62.1%) 9.7±5.1 -0.2±1.1 83.0±20.8** -0.3±0.7 -0.3±0.8 -0.2±0.9 -0.3±0.8 
Non-carriers 14 8 (57.1%) 10.5±4.3 0.3±1.4 107.0±10.7 0±0.8 0.1±0.6 0±0.9 0±0.8 
De Novo Duplication Families 
Carriers 6 3 (50.0%) 10.3±5.4 -0.3±0.8 75.5±18.5* -0.4±0.6 -0.6±0.1 -0.4±0.2 -0.5±0.0 
Non-carriers 6 4 (66.7%) 11.5±4.5 -0.5±0.8 109.8±6.8 -0.2±0.6 -0.1±0.5 0±0.5 -0.3±0.7 
*p<0.05; **p<0.01; ***p<0.0001 
FSIQ: Full-scale intelligence quotient; EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to 





Table IV: Random intercept random slope linear mixed models of BMI z-score and 16p11.2 genotype, adjusted for age and sex 
Outcome BMI z-score 
 
Parameters 
Deletion Families De Novo Deletion Families Duplication Families 
Beta Estimate p-value Beta Estimate p-value Beta Estimate p-value 
Intercept 0.42 0.03 0.26 0.24 0.03 0.94 
Deletion/Duplication (vs. Non-carrier) 0.69 0.02 1.21 0.001 0.28 0.59 
Age <5 (vs. Age ≥5) 0.46 0.51 0.58 0.38 3.69 0.01 
Male (vs. Female) -0.22 0.51 -0.02 0.94 -0.04 0.93 
Deletion/Duplication * Age -0.06 0.94 0.79 0.35 -3.14 0.02 







Table V: Linear mixed models of Eating in the Absence of Hunger behaviors and 16p11.2 deletion, adjusted for age and gender 
Outcome EAH Behavior 

















All Deletion Families* 
Intercept -0.04 0.79 -0.05 0.77 -0.02 0.91 0.09 0.69 
Deletion (vs. Non-carrier) 0.71 0.003**† 0.33 0.14 0.39 0.13 0.29 0.26 
Age <5 (vs. Age ≥5) 0.92 0.05 0.41 0.50 0.53 0.44 0.00 1.00 
Male (vs. Female) -0.63 0.00 -0.26 0.35 -0.29 0.35 0.01 0.97 
Deletion * Age -0.41 0.48 -0.60 0.38 -0.12 0.88 -0.02 0.98 
Deletion * Sex -0.11 0.73 0.26 0.45 -0.07 0.86 -0.35 0.39 
De Novo Deletion Families** 
Intercept -0.06 0.73 -0.12 0.54 0.09 0.67 0.15 0.54 
Deletion (vs. Non-carrier) 0.74 0.02 0.49 0.06 0.19 0.46 0.14 0.63 
Age <5 (vs. Age ≥5) 0.92 0.07 0.41 0.50 0.52 0.40 0.00 1.00 
Male (vs. Female) -0.60 0.01 -0.13 0.66 -0.36 0.22 0.00 0.99 
Deletion * Age -0.28 0.71 -0.79 0.26 -0.06 0.93 0.06 0.94 
Deletion * Sex -0.17 0.69 0.15 0.69 0.17 0.66 -0.15 0.73 
*Random intercept models 
**Random intercept random slope models 
†p<0.0125 (Bonferroni-corrected threshold for multiple comparisons) 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 





Table VI: Linear mixed models regressing BMI z-score on 16p11.2 deletion and Eating in the Absence of Hunger behaviors, adjusted for age and 
gender 
Outcome BMI z-score 



















All Deletion Families* 
Intercept 0.39 0.08 0.38 0.08 0.40 0.09 0.39 0.10 
Deletion (vs. Non-carrier) 0.46 0.10 0.60 0.03 0.65 0.03 0.68 0.03 
EAH Behavior 0.48 0.0003 0.52 0.0002 0.17 0.17 0.13 0.26 
Age <5 (vs. Age ≥5) -0.22 0.77 0.07 0.93 0.27 0.74 0.38 0.64 
Male (vs. Female) 0.20 0.59 0.07 0.85 -0.08 0.85 -0.14 0.73 
Deletion * Age 0.31 0.71 0.45 0.59 0.13 0.89 0.09 0.92 
Deletion * Sex 0.07 0.86 -0.09 0.83 0.13 0.79 0.16 0.73 
De Novo Deletion Families** 
Intercept 0.29 0.18 0.28 0.22 0.24 0.29 0.21 0.35 
Deletion (vs. Non-carrier) 0.80 0.01 1.01 0.0009 1.16 0.0009 1.22 0.0007 
EAH Behavior 0.55 0.0001 0.51 0.001 0.32 0.03 0.23 0.07 
Age <5 (vs. Age ≥5) -0.02 0.98 0.34 0.62 0.36 0.60 0.56 0.41 
Male (vs. Female) 0.32 0.34 0.14 0.67 0.16 0.63 0.05 0.87 
Deletion * Age 1.01 0.18 1.21 0.14 0.87 0.29 0.81 0.33 
Deletion * Sex -0.28 0.51 -0.56 0.21 -0.53 0.25 -0.46 0.33 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 
fatigue/anxiety; EAH negative: EAH due to negative affect (anger/depression) 
*Random intercept models 





Table VII: Direct and indirect effects (via EAH behaviors) of 16p11.2 deletion on BMI z-score 
Outcome BMI z-score 
 
Analysis 
Deletion Families De Novo Deletion Families 
Beta  




Estimate 95% CI p-value 
Proportion 
Mediated (%) 
EAH external    36.56    31.2 
Direct Effect 0.40 (-0.14,0.98) 0.78  0.79 (0.21,1.4) 0.15  
Indirect Effect 0.23 (0.03,0.47) <0.0001  0.36 (0.03,0.75) <0.0001  
Total Effect 0.63 (0.06,1.25) <0.0001  1.15 (0.51,1.75) 0.53  
EAH boredom    23.27    20.57 
Direct Effect 0.48 (-0.14,1.1) 0.11  0.90 (0.19,1.6) 0.06  
Indirect Effect 0.15 (-0.07,0.38) 0.21  0.23 (-0.02,0.57) 0.37  
Total Effect 0.63 (0.06,1.25) 0.04  1.13 (0.44,1.78) 0.44  
EAH fatigue    11.51    8.91 
Direct Effect 0.56 (-0.01,1.14) 0.06  1.04 (0.35,1.67) 0.003  
Indirect Effect 0.07 (-0.05,0.27) 0.37  0.10 (-0.11,0.39) 0.45  
Total Effect 0.64 (0.05,1.24) 0.03  1.14 (0.5,1.77) 0.52  
EAH negative    4.33    0.75 
Direct Effect 0.59 (-0.01,1.18) 0.06  1.12 (0.42,1.77) <0.0001  
Indirect Effect 0.03 (-0.1,0.19) 0.70  0.01 (-0.19,0.23) 0.94  
Total Effect 0.62 (0,1.2) 0.04  1.13 (0.44,1.73) 0.46  
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 




Table VIII: Direct and indirect effects (via BMI z-score) of 16p11.2 deletion on EAH Behaviors 
Outcome EAH Behaviors 
 
Analysis 
Deletion Families De Novo Deletion Families 
Beta 




Estimate 95% CI p-value 
Proportion 
Mediated (%) 
EAH external     32.37    67.9 
Direct Effect 0.38 (-0.1,0.87) 0.12  0.23 (-0.36,0.85) 0.48  
Indirect Effect 0.18 (0.01,0.44) 0.10  0.48 (0.16,0.89) 0.01  
Total Effect 0.57 (0.11,1.03) 0.01  0.70 (0.08,1.36) 0.03  
EAH boredom    55.46    73.52 
Direct Effect 0.14 (-0.29,0.58) 0.53  0.14 (-0.44,0.69) 0.65  
Indirect Effect 0.18 (0.02,0.43) 0.08  0.38 (0.11,0.76) 0.02  
Total Effect 0.32 (-0.12,0.73) 0.14  0.51 (-0.09,1.07) 0.07  
EAH fatigue    18.48    93.68 
Direct Effect 0.38 (-0.24,0.97) 0.24  0.02 (-0.66,0.74) 0.96  
Indirect Effect 0.09 (-0.04,0.3) 0.33  0.27 (0.07,0.58) 0.04  
Total Effect 0.46 (-0.11,1.03) 0.11  0.29 (-0.36,1) 0.40  
EAH negative     27.29    - 
Direct Effect 0.20 (-0.57,0.9) 0.60  -0.26 (-1.22,0.51) 1.32  
Indirect Effect 0.08 (-0.06,0.28) 0.39  0.29 (0.05,0.6) 0.05  
Total Effect 0.28 (-0.43,0.93) 0.43  0.03 (-0.82,0.78) 0.96  
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 





Table IX.A: Descriptive statistics for the AAs in the ARIC and WHI studies with individual-level SNP data available 
Study Duration N Mean Age ± SD (Range) N (%) Women Mean BMI ± SD Mean WHR ± SD N (%) Obese 
ARIC 1987-present 3,335 53.5 ± 5.8 (45-64) 2,090 (62.7%) 29.7 ± 6.3 0.9 ± 0.1 1,365 (66.3%) 
WHI 1993-1998 2,128 61.1 ± 6.8 (50-79) 2,128 (100%) 31.3 ± 6.7 0.8 ± 0.1 1,073 (76.2%) 
 
Table IX.B: Descriptive statistics for AAs in the PAGE study of FTO and obesity, with marginal SNP association data available 
Study Individual Data Available Years of Data Collection N Mean Age ± SD (Range) N (%) Women Mean BMI ± SD N (%) Obese 
ARIC Yes (3,335) 1987-present 3,297 53.8 ± 6.0 (44-66) 2,090 (62.7%) 29.7 ± 6.3 1,365 (66.3%) 
WHI Yes (2,128/5,312) 1993-1998 5,312 61.2 ± 7.2 (50-79) 5,312 (100%) 31.5 ± 6.8 2,806 (53%) 
WHI Imputed No 6,326 61.8 ± 7.1 (50-79) 6,326 (100%) 27.9 ± 5.1 3,185 (50%) 
MEC Yes (465/3,865) 1995-2004 3,865 59.5 ± 8.6 (45-77) 2,828 (73%) 28.5 ± 5.5 1,202 (31%) 
HyperGEN No 1996-2003 1,171 47.9 ± 12.4 (20-85) 780 (67%) 32.5 ± 7.2 680 (58%) 
GenNet No 1995-2003 517 38.3 ± 7.6 (20-64) 296 (57%) 30.5 ± 8.2 224 (43%) 

















AA CUX1 SNP  
rs1421085 
 
ARIC MAF 0.108 




ARIC MAF 0.112 
WHI MAF 0.132 
Eur CUX1 SNP  
rs8050136 
 
ARIC MAF 0.438 
WHI MAF 0.44 
AA SNP  
rs3751812 
 
ARIC MAF 0.106 
WHI MAF 0.128 
Eur SNP  
rs9939609 
 
ARIC MAF 0.481 
WHI MAF 0.477 
AA SNP  
rs17817964 
 
ARIC MAF 0.111 
WHI MAF 0.135 
IRX3 eQTL  
rs9930506 
 
ARIC MAF 0.211 
WHI MAF 0.233 
0.463 0.465 T A C G A C A 
0.040 0.034 T A C G T C A 
0.280 0.263 T A A G T C A 
0.046 0.042 T A A G T C G 
0.052 0.053 T A C G A C G 
  0.105 0.127 C T A T T T G 
Minor alleles are in bold. Blue SNPs were associated with obesity in Europeans only. Red SNPs were associated with obesity in AAs only. 
MAF: Minor allele frequency; eQTL: Expression Quantitative Locus 
 
Table X.B: Mean BMI and WHR Among FTO Haplotype Carriers in the ARIC and WHI Cohorts 
 ARIC WHI 
Haplotype Mean BMI ± SD Mean WHR ± SD Mean BMI ± SD Mean WHR ± SD 
TTCGACA 29.6 ± 6.4 0.9 ± 0.1 31.4 ± 6.8 0.8 ± 0.1 
TTCGTCA 29.8 ± 6.2 0.9 ± 0.1 31.2 ± 6.5 0.8 ± 0.1 
TTAGTCA 29.8 ± 6.5 0.9 ± 0.1 31.0 ± 6.4 0.8 ± 0.1 
TTAGTCG 29.4 ± 5.5 0.9 ± 0.1 31.4 ± 6.6 0.8 ± 0.1 
TTCGACG 29.5 ± 5.9 0.9 ± 0.1 31.3 ± 6.8 0.8 ± 0.1 






Table X.C: Effect of the CTATTTG Haplotype on ln(BMI) and WHR in the ARIC and WHI Cohorts 
  Outcome: ln(BMI)  Outcome: WHR 
Study Group N  Beta Estimate 95% CI F-statistic and p-value  Beta Estimate 95% CI F-statistic and p-value 
ARIC ARIC 3,335 0.015 (0,0.031) F=3.68; p=0.055 0 (-0.006,0.005) F=0.018; p=0.893 
  
ARICgt60 3,023  0.019 (0.002,0.036) F=4.65; p=0.031  -0.001 (-0.007,0.005) F=0.119; p=0.730 
ARICgt70 2,621 0.017 (-0.002,0.036) F=3; p=0.083 -0.001 (-0.008,0.006) F=0.123; p=0.726 
ARICgt80 1,824 0.020 (-0.004,0.045) F=2.75; p=0.097 0.074 (-0.012,0.006) F=0.373; p=0.541 
  
ARIC_F 2,076  0.022 (0.0001,0.043) F=3.88; p=0.049  -0.001 (-0.009,0.007) F=0.064; p=0.8 
ARIC_M 1,235 0.005 (-0.017,0.027) F=0.196; p=0.658 0 (-0.007,0.007) F=0.003; p=0.957 
  
WHI WHI 2,128  0.002 (0.018,0.021) F=0.023; p=0.88  0.004 (-0.002,0.011) F=0.057; p=0.812 
 
WHIgt60 1,807  -0.007 (-0.029,0.015) F=0.399; p=0.528  0.006 (-0.001,0.014) F=2.62; p=0.105 
WHIgt70 1,520 0.032 (-0.050,0.113) F=0.585; p=0.446 0.013 (-0.016,0.043) F=0.783; p=0.377 
WHIgt80 1,020 0.028 (-0.083,0.139) F=0.245; p=0.622 0.016 (-0.025,0.057) F=0.575; p=0.45 
ARICg60/70/80: ARIC subjects with ≥60/70/80% markers shared with YRI trios; ARIC_F: ARIC females; ARIC_M: ARIC males;  










AA CUX1 SNP  
rs1421085 
 
ARIC MAF 0.108 




ARIC MAF 0.112 
WHI MAF 0.132 
AA SNP  
rs3751812 
 
ARIC MAF 0.106 
WHI MAF 0.128 
AA SNP  
rs17817964 
 
ARIC MAF 0.111 
WHI MAF 0.135 
 0.861 T A G C 
 0.127 C T T T 
Minor alleles are in bold. Red SNPs were associated with obesity in AAs only. 
MAF: Minor allele frequency; eQTL: Expression Quantitative Locus 
 
Table XI.A.2: Mean BMI and WHR Among Carriers of FTO Haplotypes Derived from African Obesity-Associated SNPs, in the ARIC and WHI 
Cohorts 
 ARIC WHI 
Haplotype Mean BMI ± SD Mean WHR ± SD Mean BMI ± SD Mean WHR ± SD 
TAGC 29.7 ± 6.2 0.9 ± 0.1 31.4 ± 6.7 0.8 ± 0.1 
CTTT 29.8 ± 6.3 0.9 ± 0.1 31.1 ± 6.6 0.8 ± 0.1 
 
 











Eur CUX1 SNP  
rs8050136 
 
ARIC MAF 0.438 
WHI MAF 0.44 
Eur SNP  
rs9939609 
 
ARIC MAF 0.481 
WHI MAF 0.477 
0.519 0.523 C A 
0.043 0.037 C T 
0.438 0.440 A T 
Minor alleles are in bold. Blue SNPs were associated with obesity in Europeans only. 
MAF: Minor allele frequency; eQTL: Expression Quantitative Locus 
 
Table XI.B.2: Mean BMI and WHR Among Carriers of FTO Haplotypes Derived from European Obesity-Associated SNPs, in the ARIC and WHI 
Cohorts 
 ARIC WHI 
Haplotype Mean BMI ± SD Mean WHR ± SD Mean BMI ± SD Mean WHR ± SD 
CA 29.6 ± 6.3 0.9 ± 0.1 31.4 ± 6.8 0.8 ± 0.1 
CT 30.0 ± 6.1 0.9 ± 0.1 31.7 ± 7.1 0.8 ± 0.1 






Table XI.C: BMI Among ARIC and WHI Subjects with Haplotypes Derived from European and African Obesity-Associated SNPs 
 
African and European SNPs 
ARIC 
 rs8050136/rs9939609 Haplotype 
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31.1 ± 6.3 31.4 ± 7.6 31.0 ± 6.8 
 
 





































African SNPs + rs9930506 and European SNPs 
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31.1 ± 6.3 31.4 ± 7.6 30.9 ± 6.8 
 
 
African SNPs and European SNPs + rs9930506  
ARIC 

















 rs8050136/rs9939609/rs9930506 Haplotype 













30.9 ± 6.1 32.7 ± 7.9 31.4 ± 7.6 46.2 30.9 ± 6.8 
 




Table XII: Functional Annotations Influencing the Probability of FTO SNPs’ Direct Relevance to Obesity in AAs, in Models Assuming Two Causal 
SNPs Underlie the FTO-Obesity Relationship 
EID Epigenome Name Tissue (Cell Type) Annotation p-value 
E066 Liver Liver EnhAc 0.058 
E074 Brain Substantia Nigra Brain Tx5 0.064 
E023 Mesenchymal Stem Cell Derived Adipocyte Cultured Cells Fat (Mesenchymal) EnhAc 0.066 
E049 Mesenchymal Stem Cell Derived Chondrocyte Cultured Cells Stromal Connective (Mesenchymal) EnhAc 0.066 
E049 Mesenchymal Stem Cell Derived Chondrocyte Cultured Cells Stromal Connective (Mesenchymal) Tx5 0.069 
E023 Mesenchymal Stem Cell Derived Adipocyte Cultured Cells Fat (Mesenchymal) Tx5 0.085 







Table XIII: FTO SNPs’ Posterior Probability of Association with Obesity in AAs in Models Assuming Two Causal SNPs Underlie the FTO-Obesity 
Relationship 
rsID Position on Chr16 Alt Allele Ref Allele MAF Beta Z-score P-value PPA Overlapping Significant Annotations 
rs6499640 53769677 G A 0.35 -0.05 -0.25 8.10E-01 0.00  
rs72803664 53784911 A G 0.11 -0.13 -0.36 7.10E-01 0.00  
rs1108102 53789508 A T 0.14 -0.09 -0.32 7.40E-01 0.00  
rs1421085 53800954 C T 0.12 1.11 3.54 3.00E-04 0.00  
rs11642015 53802494 T C 0.11 1.09 3.47 4.90E-04 0.00  
rs62048402 53803223 A G 0.12 1.13 3.60 2.40E-04 0.00  
rs1558902 53803574 A T 0.12 1.13 3.28 1.00E-03 0.00  
rs56094641 53806453 G A 0.12 1.12 3.57 2.80E-04 0.00  
rs55872725 53809123 T C 0.11 1.09 3.47 5.30E-04 0.00  
rs1121980 53809247 A G 0.47 0.35 1.83 7.20E-02 0.00  
rs62033400 53811788 G A 0.12 1.35 4.41 1.10E-05 0.00  
rs16945088 53812524 G A 0.29 -0.16 -0.76 4.50E-01 0.00  
rs8057044 53812614 G A 0.29 -0.27 -1.29 2.10E-01 0.00  
rs17817449 53813367 G T 0.39 0.37 1.84 5.90E-02 0.00  
rs17817497 53815435 C T 0.11 0.99 3.16 1.80E-03 0.00  
rs8050136 53816275 A C 0.44 0.42 2.08 3.20E-02 0.00  
rs113191842 53817318 A G 0.06 1.23 2.77 5.70E-03 0.00  
rs3751812 53818460 T G 0.11 1.02 3.25 1.20E-03 0.00  
rs9939609 53820527 T A 0.48 0.04 0.21 8.20E-01 0.00  
rs9927317 53820996 G C 0.26 0.85 3.83 1.50E-04 0.94 E023 Tx5, E049 Tx5, E074 Tx5 
rs17817712 53821125 G A 0.11 1.03 3.28 1.10E-03 0.00  
rs62033405 53822387 T C 0.12 1.35 4.30 1.40E-05 0.99 E023 EnhAc, E049 EnhAc 
rs79994966 53823727 C T 0.11 1.34 4.27 1.80E-05 0.00  
rs28432761 53823878 C T 0.19 0.83 3.29 9.70E-04 0.00  
rs11647020 53823990 T C 0.2 0.73 2.89 3.50E-03 0.00  
rs11646715 53824007 A G 0.19 0.84 3.20 1.10E-03 0.00  
rs62033406 53824226 G A 0.14 0.85 3.00 2.50E-03 0.00  
rs9941349 53825488 T C 0.19 0.69 2.73 5.40E-03 0.00  
rs56137030 53825905 A G 0.12 1.35 4.41 8.30E-06 0.00  
rs28567725 53826028 C T 0.22 0.87 3.59 2.40E-04 0.00  
rs9931494 53827179 G C 0.19 0.94 3.72 1.60E-04 0.00  
rs10468280 53827479 G A 0.11 1.01 3.22 1.40E-03 0.00  
rs62033408 53827962 G A 0.11 1.03 3.28 1.10E-03 0.00  
rs17817964 53828066 T C 0.12 1.02 3.36 8.60E-04 0.00  
rs62033413 53830055 G C 0.12 1.33 4.34 1.40E-05 0.00  
rs9930506 53830465 G A 0.22 0.66 2.72 5.50E-03 0.00  
rs9933040 53830867 A T 0.22 0.65 2.68 6.00E-03 0.00  
rs9922708 53831146 T C 0.21 0.64 2.44 1.60E-02 0.00  
rs72805611 53831354 T C 0.12 0.97 3.20 1.30E-03 0.00  
rs9922619 53831771 T G 0.19 0.69 2.73 5.70E-03 0.00  
rs7204609 53833605 C T 0.34 -0.16 -0.76 4.30E-01 0.00  
rs7188250 53834607 C T 0.12 1.34 4.38 1.30E-05 0.01  
rs72805612 53834608 A G 0.12 1.36 4.33 1.40E-05 0.01  
rs11075993 53837144 T G 0.12 0.98 3.12 5.00E-01 0.00  
rs72805613 53837342 G A 0.12 0.89 2.93 3.30E-03 0.00  
rs8044769 53839135 T C 0.25 -0.33 -1.50 1.30E-01 0.00  
rs12149832 53842908 A G 0.12 0.92 2.93 2.50E-03 0.00  




rs11642841 53845487 A C 0.11 0.88 2.72 5.70E-03 0.00  
rs7191513 53990523 G A 0.46 -0.03 -0.15 8.70E-01 0.00  
rs9932411 54005163 T C 0.33 0.12 0.57 5.50E-01 0.00  
Minor alleles are in bold. Significant functional annotations overlapping with the two highest-PPA SNPs are indicated. 
MAF: Minor Allele Frequency; PPA: Posterior Probability of Association 




















Figure 3: Directed acyclic graph depicting hypothesized relationships between 16p11.2 genotype, 











































Figure 5: BMI z-score vs. age among deletion carriers at all ages with growth measurements available.  
Box plots depict the median, 25th, and 75th percentile values, and are joined at their median values. 
Whiskers represent 5th and 95th percentile values. Numbers below the graph represent the number of 
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Figure 6: Summary diagram of associations identified in 16p11.2 deletion families.  
Solid lines indicate relationships of primary interest in this study, while dotted lines represent associations 
involving variables of secondary interest. Variables’ temporal order (if known) and associations’ estimate 




























Figure 7: Obesity-associated SNPs in intron 1 of FTO 
Blue SNPs are associated with obesity in Europeans. Red SNPs are associated with obesity in African 
Americans (AAs). Red linkage disequilibrium (r2) values pertain to AAs from the 1000 Genomes African 
Southwest (ASW) population. SNPs within putative Cut-like homeobox 1 (CUX1) binding sites are in bold. 
 






















































Figure 8: FTO SNPs with the highest posterior probability of association (PPA) with obesity in AAs 
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A1: Eating in the Absence of Hunger Questionnaire (Parent Report for Child) 
 
Name:           Date: 
Study No:   
 




 How often does your 
child… 
Never  Rarely Some- 
times 
Often Always On average, how 
many days a 
week? (0-7) 
 …eat dinner at a 
restaurant? 
  




Imagine that your child is eating a meal or snack at home, school, or in a restaurant.  Imagine that your 
child eats enough of the meal so that your child is no longer hungry.  
 
 In this situation, how often 
does your child keep 
eating because 
Never  Rarely Some- 
times 
Often Always On average, how 
many days a 
week? (0-7) 
1. … the food looks, tastes or 
smells so good? 
      
2. … others are still eating?       
3. … your child is feeling sad 
or depressed? 
      
4. … your child is feeling 
bored? 
      
5. … your child is feeling 
angry or frustrated? 
      
6. … your child is feeling 
tired? 
      
7. … your child is feeling 
anxious or nervous? 
      





 In this situation, how often 
does your child start 
eating because your 
child… 
Never  Rarely Some- 
times 
Often Always On average, how 
many days a 
week? (0-7) 
8. … is near food that looks, 
tastes or smells so good? 
      
9. … is with other people 
who are eating? 
      
10. … is feeling sad or 
depressed? 
      
11. … is feeling bored?       
12. … is feeling angry or 
frustrated? 
      
13. … is feeling tired?       
14. … is feeling anxious or 
nervous 








A2: Loss of Control Eating Disorder (LOC-ED) Questionnaire – Child Self-Report 
 
 Question 
1  During the past 3 months have you ever felt that you were not able to stop eating, or not able to 
control the type of food or amount of food that you ate? 
2a  How many times did this happen in the past month? 
2b  How many times did this happen between 30-60 days ago? 
2c  How many times did this happen between 60-90 days ago? 
3  Were you hungry? 
4  Were you trying to cut back or eat less food than usual? 
5  Did you have a bad feeling, like angry, sad, or lonely before you ate? 
6  Were you feeling bored or tired before you ate? 
7  Did something bad happen to make you want to eat? 
8  Did something good happen to make you want to eat? 
9  Did you keep eating even though you were full or had already eaten enough? 
10  Did the amount of food feel like too much for you at the time? 
11  Do you think other people would think you ate too much food? 
12  Were you eating in secret or trying to hide the food you were eating? 
13  Did it feel like you were eating more than others? 
14  During any time when you were eating, did you feel numb or like you spaced or zoned out? 
15  Did you feel badly about yourself for eating or about what you ate? 
16  Did you throw up? 
16b  If you did throw up, did you make yourself throw up? 
17  Did you use laxatives or any kind of pills to make the food go out of your body? 
18  Did you exercise for an hour or more, in order to make up for the food that you ate? 
19  Did you not eat anything at all for a whole day or more because you ate too much? 
 
Scoring Criteria for LOC-ED: 
 
1) YES to Question 1 (LOC over eating) 
 
2) YES to Question 9 or 10 (eating in the absence of hunger)  
 
3) Question 2 = ≥2 episodes, for the past 3 months 
 
4) YES to three or more of the following: 
a. Question 5, 6, or 7 (Eating in response to negative affect) 
b. Question 12 (Secrecy regarding the episode) 
c. Question 11 or 13 (Eating more, or the perception of eating more, than others)  
d. Question 14 (Feelings of numbness/lack of awareness while eating)          
e. Question 15 (Negative affect following eating) 
 




A3: Child Feeding Questionnaire (CFQ) – Parent Report for Child 
 





Half of the 
Time 
4 







When your child is at 
home, how often are 
you responsible for 












2 How often are you 
responsible for deciding 
what your child’s 
portion sizes are? 
 
1 2 3 4 5 
3 How often are you 
responsible for deciding 
if your child has eaten 
the right kind of foods? 
 
1 2 3 4 5 



























5 Your adolescence 1 2 3 4 5 
6 Your 20s 1 2 3 4 5 
7 At present 1 2 3 4 5 
8 Your child during the 
first year of life 
1 2 3 4 5 
9 Your child as a toddler 1 2 3 4 5 
10 Your child as a pre-
schooler 
1 2 3 4 5 
11 Your child kindergarten 
through 2nd grade 
1 2 3 4 5 
12 Your child from 3rd 
through 5th grade 
1 2 3 4 5 
13 Your child from 6th 
through 8th grade 
 
1 2 3 4 5 
















How concerned are you 
about your child eating 
too much when you are 













15 How concerned are you 
about your child having 
to diet to maintain a 
desirable weight? 
 
1 2 3 4 5 
16 How concerned are you 
about your child 
becoming overweight? 
 
1 2 3 4 5 
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17 I have to be sure that my 
child does not eat too 
many sweets (candy, ice 
cream, cake or pastries) 
 
1 2 3 4 5 
18 I have to be sure that my 
child does not eat too 
many high-fat foods 
 
1 2 3 4 5 
19 I have to be sure that my 
child does not eat too 
much of her or his favorite 
foods 
 
1 2 3 4 5 
20 I intentionally keep some 
foods out of my child’s 
reach 
 
1 2 3 4 5 
21 I offer sweets (candy, ice 
cream, cake, pastries) to 
my child as a reward for 
good behavior 
 
1 2 3 4 5 
22 I offer my child her or his 
favorite foods in 
exchange for good 
behavior 
 
1 2 3 4 5 
23 If I did not guide or 
regulate my child’s eating, 
she or he would eat too 
many junk foods 
 
1 2 3 4 5 
24 If I did not guide or 
regulate my child’s eating, 
she or he would eat too 
much of her favorite foods 
 
1 2 3 4 5 
25 My child should always 
eat all of the food on her 
or his plate 
 
1 2 3 4 5 
26 I have to be especially 
careful to make sure my 
child eats enough 
 
1 2 3 4 5 
27 If my child says “I’m not 
hungry,” I try to get her or 
him to eat anyway 
 
1 2 3 4 5 
28 If I did not guide or 
regulate my child’s eating, 
she would eat much less 
than she or he should 
 
1 2 3 4 5 













How much do you keep track of the 
sweets (candy, ice cream, cake, 












30 How much to you keep track of the 
snack food (potato chips, Doritos, 
1 2 3 4 5 
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cheese puffs) that your child eats? 
 
31 How much do you keep track of the 
high-fat foods that your child eats? 






A4: Factor Analysis Results Summaries 
A4.1: Factor Analysis: Eating in the Absence of Hunger (EAH) – Parental Report for Children 
	
A factor analysis of 14-item parental reports of EAH generated four factors. Each of the first three 
factors contained 4 items, and the last factor contained 2 items. Specifically, Factor 1 consisted of two 
pairs of responses regarding anger/frustration and sadness/depression, Factor 2 comprised two pairs of 
responses regarding external and social cues, Factor 3 represented two pairs of responses regarding 
anxiety/nervousness and fatigue, and Factor 4 included one pair of responses regarding boredom 
(Appendix A5.1). Factor 1 was named EAH due to negative affect (EAH negative), Factor 2 was named 
EAH due to external cues (EAH external), Factor 3 was named EAH due to fatigue/anxiety (EAH fatigue), 
and Factor 4 was named EAH due to boredom (EAH boredom). All four subscales demonstrated good 
internal consistency: Cronbach’s alpha values for the EAH negative, EAH external, EAH fatigue, and EAH 
boredom subscales were 0.88, 0.87, 0.93, and 0.85, respectively. The subscales were positively 
correlated (r=0.38-0.66; Appendix A5.2). 
A4.2: Factor Analysis: Eating in the Absence of Hunger (EAH) – Parental Self-Report 
	
For parental self-reports of EAH, factor analysis of the same 14-item questionnaire generated 
three factors. The first factor contained 8 items, and second factor contained 6 items, and the last factor 
contained 2 items. Factor 1 included four pairs of responses regarding anger/frustration, 
sadness/depression, anxiety/nervousness, and boredom, Factor 2 consisted of three pairs of responses 
regarding external cues, social cues, and boredom, and Factor 3 contained a pair of responses regarding 
fatigue (Appendix A5.3). Factor 1 was named EAH due to negative affect (EAH negative), Factor 2 was 
named EAH due to external cues (EAH external), and Factor 3 was named EAH due to fatigue (EAH 
fatigue). Cronbach’s alpha values for the EAH negative, EAH external, and EAH fatigue subscales were 
0.93, 0.84, and 0.88, respectively. The subscales were positively correlated (r=0.44-0.57; Appendix A5.4). 
A4.3: Factor Analysis: Parental Restriction and Pressure to Eat 
	
 The factor analysis of parents’ responses to the 31-item Child Feeding Questionnaire yielded 8 
factors, but I focused on the two factor patterns that directly correspond to parental restriction and 
pressure to eat, as these two constructs were previously associated with both disinhibited eating and BMI 
[101]. My factor analysis results corresponded well with a previous confirmatory factor analysis [95]: as 
expected, the questions directly related to restriction and pressure to eat loaded onto the factors 
previously reported to underlie restriction and pressure to eat, respectively (Appendix A5.5). Cronbach’s 
alpha values for the restriction and pressure to eat subscales were 0.92 and 0.78, respectively, and the 




A5: Factor Analysis Results 
A5.1: Estimated factor loadings, item variances, and factor variances for the final 4-factor model of EAH questionnaire responses (Parental 
reports for children) 
 Factor 1  
(EAH negative) 
Factor 2  
(EAH external) 
Factor 3  
(EAH fatigue) 




How often does your child keep eating because …      
… your child is feeling angry or frustrated 0.81    0.78 
… your child is feeling sad or depressed? 0.71    0.69 
… the food looks, tastes or smells so good?  0.69   0.53 
… others are still eating?  0.55   0.54 
… your child is feeling anxious or nervous?   0.71  0.81 
… your child is feeling tired?   0.48  0.59 
… your child is feeling bored?    0.61 0.67 
How often does your child start eating because your 
child… 
     
… is feeling angry or frustrated? 0.80    0.85 
… is feeling sad or depressed? 0.75    0.81 
… is near food that looks, tastes or smells so good?  0.84   0.68 
… is with other people who are eating?  0.78   0.68 
… is feeling anxious or nervous?   0.71  0.74 
… is feeling tired?   0.51  0.73 
… is feeling bored?    0.66 0.69 
Factor Variance 1.47 1.66 0.90 0.86  
Factor loadings less than 0.3 are not shown. 
Communality estimates represent the proportion of the item’s variance accounted for by the factors. 
A5.2: Estimated factor-factor correlations for the final 4-factor model 
 EAH negative EAH external EAH fatigue EAH boredom 
EAH negative -    
EAH external 0.38 -   
EAH fatigue 0.66 0.41 -  





A5.3: Estimated factor loadings, item variances, and factor variances for the final 3-factor model of EAH questionnaire responses (Parental self-
reports) 
 Factor 1  
(EAH negative) 
Factor 2  
(EAH external) 




How often do you keep eating because …     
… you feel angry or frustrated 0.63  0.34 0.72 
… you feel sad or depressed? 0.89   0.73 
… the food looks, tastes or smells so good?  0.55  0.38 
… others are still eating?  0.61  0.46 
… you feel anxious or nervous? 0.63  0.37 0.71 
… you feel tired?   0.68 0.69 
… you feel bored? 0.50 0.49  0.64 
How often do you start eating because you …     
… feel angry or frustrated? 0.64  0.34 0.78 
… feel sad or depressed? 0.87   0.77 
… are near food that looks, tastes or smells so good?  0.66  0.47 
… are with other people who are eating?  0.74  0.54 
… feel anxious or nervous? 0.65  0.35 0.74 
… feel tired?   0.66 0.73 
… feel bored? 0.50 0.47  0.65 
Factor Variance 2.14 1.55 0.95  
Factor loadings less than 0.3 are not shown. 
Communality estimates represent the proportion of the item’s variance accounted for by the factors. 
A5.4: Estimated factor-factor correlations for the final 3-factor model 
 EAH negative EAH external EAH fatigue 
EAH negative -   
EAH external 0.52 -  






A5.5: Estimated factor loadings, item variances, and factor variances for the subset of Child Feeding Questionnaire responses underlying 
Restriction and Pressure to Eat 
 Factor 1 
(Restriction) 
Factor 2 
(Pressure to Eat) 
Communality Estimate 
Question    
I have to be sure that my child does not eat too much of her favorite 
foods 
0.86  0.71 
I have to be sure that my child does not eat too many high-fat foods 1.00  0.71 
I have to be sure that my child does not eat too many sweets (candy, 
ice-cream, cake or pastries) 
0.96  0.72 
If I did not guide or regulate my child's eating, she would eat too 
many junk foods 
0.92  0.72 
If I did not guide or regulate my child's eating, she would eat too 
much of her favorite foods 
0.86  0.69 
I intentionally keep some foods out of my child's reach 0.83  0.60 
If I did not guide or regulate my child's eating, she would eat much 
less than she should 
 1.00 0.71 
I have to be especially careful to make sure my child eats enough  0.98 0.71 
If my child says ``I'm not hungry'', I try to get her to eat anyway  0.91 0.56 
My child should always eat all of the food on her plate  0.43 0.29 
Factor Variance 2.48 1.62  
Factor loadings less than 0.3 are not shown. 





A6: Assessment of Confounding by Autism 
A6.1: Random intercept linear mixed models of BMI z-score and autism spectrum disorder 
Outcome BMI z-score 
 
Parameters 
Deletion Families De Novo Deletion Families Duplication Families 
Beta Estimate p-value Beta Estimate p-value Beta Estimate p-value 
Intercept 1.04 <0.0001 1.25 <0.0001 -0.04 0.88 






A7: Assessment of Confounding by Parental Feeding Practices 
A7.1: Random intercept linear mixed models regressing BMI z-score on parental feeding practices 
Outcome BMI z-score 
Parental Feeding Practice Parental Restriction Parental Pressure to Eat 
 Beta Estimate p-value Beta Estimate p-value 
Intercept 0.80 <0.0001 0.75 <0.0001 
Parental feeding Practice 0.63 <0.0001 -0.71 <0.0001 
A7.2:  Random intercept linear mixed models of Eating in the Absence of Hunger behaviors and parental feeding practices, adjusted for age and 
sex, in deletion families 
Outcome EAH Behavior 



















Intercept 0.25 0.04 0.11 0.30 0.19 0.20 0.21 0.20 
Restriction 0.49 <0.0001 0.39 0.0002 0.16 0.17 0.03 0.82 
Age <5 (vs. Age ≥5) 0.10 0.81 -0.42 0.24 -0.02 0.97 -0.30 0.51 
Male (vs. Female) -0.46 0.01 -0.01 0.93 -0.31 0.10 -0.17 0.39 
Restriction * Age 0.26 0.46 -0.16 0.58 0.26 0.46 0.16 0.67 
Restriction * Sex -0.02 0.91 0.27 0.06 0.23 0.19 0.34 0.08 
Parental Pressure to Eat 
Intercept 0.18 0.22 0.09 0.52 0.26 0.12 0.32 0.07 
Pressure to Eat -0.35 0.04 -0.26 0.07 0.03 0.84 0.15 0.38 
Age <5 (vs. Age ≥5) 0.81 0.02 -0.03 0.92 0.47 0.21 0.03 0.94 
Male (vs. Female) -0.41 0.04 0.00 1.00 -0.38 0.07 -0.29 0.18 
Restriction * Age -0.35 0.32 0.23 0.48 -0.06 0.86 0.07 0.86 
Restriction * Sex 0.00 0.99 -0.21 0.32 -0.27 0.26 -0.37 0.14 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 




A8: Assessment of Confounding by Parental EAH Behaviors 
A8.1: Random intercept linear mixed models regressing BMI z-score on maternal self-reports of Eating in the Absence of Hunger behaviors, 
adjusted for child age and sex, in deletion families 
Outcome BMI z-score 
EAH Behavior EAH external EAH fatigue EAH negative 
Parameters Beta Estimate p-value Beta Estimate p-value Beta Estimate p-value 
Intercept 0.86 <0.0001 0.88 <0.0001 0.94 <0.0001 
Maternal EAH Behavior 0.12 0.42 0.10 0.50 -0.07 0.69 
Child Age <5 (vs. Age ≥5) 0.93 0.27 1.50 0.04 -0.09 0.92 
Male (vs. Female) Child 0.01 0.98 -0.01 0.96 -0.09 0.74 
Maternal EAH * Child Age -0.21 0.84 -0.75 0.18 0.72 0.33 
Maternal EAH * Child Sex -0.08 0.76 0.00 0.99 0.23 0.37 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 
fatigue/anxiety; EAH negative: EAH due to negative affect (anger/depression) 
A8.2: Random intercept linear mixed models regressing BMI z-score on paternal self-reports of Eating in the Absence of Hunger behaviors, 
adjusted for child age and sex, in deletion families 
Outcome BMI z-score 
EAH Behavior EAH external EAH fatigue EAH negative 
Parameters Beta Estimate p-value Beta Estimate p-value Beta Estimate p-value 
Intercept 0.88 <0.0001 0.90 <0.0001 0.94 <0.0001 
Paternal EAH Behavior -0.22 0.20 -0.12 0.55 0.07 0.71 
Child Age <5 (vs. Age ≥5) 0.63 0.46 0.65 0.45 0.68 0.43 
Male (vs. Female) Child 0.24 0.46 0.17 0.60 0.13 0.70 
Paternal EAH * Child Age 0.70 0.57 0.64 0.60 0.64 0.60 
Paternal EAH * Child Sex 0.29 0.47 0.17 0.67 0.05 0.91 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 






A8.3:  Random intercept linear mixed models regressing BMI z-score on maternal self-reports of Eating in the Absence of Hunger behaviors, 
adjusted for child age and sex, in de novo deletion families 
Outcome BMI z-score 
EAH Behavior EAH external EAH fatigue EAH negative 
Parameters Beta Estimate p-value Beta Estimate p-value Beta Estimate p-value 
Intercept 0.84 0.0003 0.86 0.0003 0.92 0.0003 
Maternal EAH Behavior 0.18 0.36 0.13 0.51 -0.06 0.78 
Child Age <5 (vs. Age ≥5) 1.24 0.17 2.37 0.01 0.90 0.48 
Male (vs. Female) Child -0.02 0.96 -0.05 0.87 -0.13 0.67 
Maternal EAH * Child Age -0.22 0.84 -1.19 0.06 0.07 0.94 
Maternal EAH * Child Sex -0.13 0.64 -0.03 0.92 0.24 0.41 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 
fatigue/anxiety; EAH negative: EAH due to negative affect (anger/depression) 
A8.4:  Random intercept linear mixed models regressing BMI z-score on paternal self-reports of Eating in the Absence of Hunger behaviors, 
adjusted for child age and sex, in de novo deletion families 
Outcome BMI z-score 
EAH Behavior EAH external EAH fatigue EAH negative 
Parameters Beta Estimate p-value Beta Estimate p-value Beta Estimate p-value 
Intercept 0.87 0.0003 0.87 0.0003 0.91 0.0002 
Paternal EAH Behavior -0.10 0.57 -0.06 0.77 0.13 0.49 
Child Age <5 (vs. Age ≥5) 0.76 0.39 0.77 0.38 0.79 0.37 
Male (vs. Female) Child 0.17 0.62 0.14 0.68 0.10 0.77 
Paternal EAH * Child Age -0.21 0.89 -0.28 0.85 -0.29 0.84 
Paternal EAH * Child Sex 0.35 0.40 0.30 0.46 0.15 0.73 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 






A9: Assessment of Confounding by Full-Scale IQ 
A9.1:  Random intercept linear mixed models of full-scale IQ and 16p11.2 genotype, adjusted for age and gender 
Outcome FSIQ 













Intercept 102.38 <0.0001 103.53 <0.0001 96.48 <0.0001 
Deletion/Duplication (vs. Non-carrier) -13.88 <0.0001 -9.69 0.0002 -6.93 0.06 
Age <5 (vs. Age ≥5) -65.71 0.001 -23.72 0.45 -76.37 <0.0001 
Male (vs. Female) -70.83 <0.0001 -82.69 <0.0001 -82.08 <0.0001 
Deletion/Duplication * Age 0.68 0.0026 0.23 0.4938 0.82 <0.0001 
Deletion/Duplication * Sex 0.76 <0.0001 0.85 <0.0001 0.89 <0.0001 
*p<0.05, **p<0.01, ***p<0.0001 
A9.2:  Random intercept linear mixed models of Eating in the Absence of Hunger behaviors and full-scale IQ in deletion families 
Outcome EAH Behavior 


















All Deletion Families 
Intercept 1.28 0.01 1.07 0.02 0.50 0.32 0.13 0.79 
FSIQ -0.01 0.02 -0.01 0.03 0.00 0.40 0.00 0.99 
De Novo Deletion Families 
Intercept 1.32 0.06 1.50 0.01 0.33 0.57 0.18 0.77 
FSIQ -0.01 0.07 -0.01 0.02 0.00 0.67 0.00 0.96 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 







A9.3:  Random intercept linear mixed models regressing EAH behaviors on 16p11.2 deletion and full-scale IQ, adjusted for age and gender 
Outcome EAH Behavior 


















All Deletion Families 
Intercept 0.14 0.84 0.39 0.56 -0.48 0.53 -0.35 0.66 
Deletion (vs. Non-carrier) 0.58 0.05 0.22 0.41 0.44 0.14 0.35 0.25 
FSIQ 0.00 0.76 0.37 0.56 0.00 0.53 0.00 0.59 
Age <5 (vs. Age ≥5) 0.99 0.15 -0.26 0.36 0.64 0.36 0.12 0.87 
Male (vs. Female) -0.57 0.07 -0.42 0.55 -0.31 0.32 0.00 0.99 
Deletion * Age -0.09 0.91 0.28 0.42 0.09 0.91 0.16 0.85 
Deletion * Sex -0.06 0.86 0.00 0.49 -0.05 0.90 -0.34 0.40 
De Novo Deletion Families 
Intercept 0.37 0.69 0.42 0.62 -0.47 0.59 0.07 0.94 
Deletion (vs. Non-carrier) 0.70 0.04 0.40 0.17 0.28 0.34 0.15 0.63 
FSIQ 0.00 0.61 -0.01 0.50 0.01 0.51 0.00 0.95 
Age <5 (vs. Age ≥5) 0.90 0.21 0.36 0.56 0.57 0.37 0.02 0.98 
Male (vs. Female) -0.49 0.15 -0.13 0.66 -0.37 0.22 0.00 0.99 
Deletion * Age -0.19 0.82 -0.72 0.32 -0.08 0.91 0.10 0.90 
Deletion * Sex -0.35 0.43 0.13 0.74 0.16 0.68 -0.21 0.64 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 






A10: Analysis of Duplication Carriers 
A10.1: Random intercept linear mixed models regressing BMI z-score on 16p11.2 duplication and Eating in the Absence of Hunger behaviors, 
adjusted for age and gender 
Outcome BMI z-score 

















Intercept 0.34 0.50 0.33 0.49 0.19 0.69 0.29 0.54 
Duplication (vs. Non-carrier) -0.36 0.55 -0.42 0.50 -0.38 0.52 -0.15 0.81 
EAH Behavior 0.04 0.88 -0.12 0.59 -0.40 0.31 0.56 0.25 
Age <5 (vs. Age ≥5) 3.50 0.01 3.33 0.01 3.48 0.01 3.68 0.01 
Male (vs. Female) -0.60 0.38 -0.57 0.37 -0.42 0.50 -0.42 0.53 
Duplication * Age -3.00 0.04 -2.78 0.04 -2.85 0.03 -3.19 0.03 
Duplication * Sex 0.28 0.73 0.26 0.74 0.07 0.93 0.24 0.76 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 
fatigue/anxiety; EAH negative: EAH due to negative affect (anger/depression) 
A10.2:  Linear mixed models of Eating in the Absence of Hunger behaviors and 16p11.2 duplication, adjusted for age and gender 
Outcome EAH Behavior 


















Intercept -0.43 0.19 0.24 0.54 -0.04 0.90 0.11 0.75 
Duplication (vs. Non-carrier) 0.08 0.85 -0.66 0.19 -0.07 0.81 -0.14 0.72 
Age <5 (vs. Age ≥5) -0.65 0.42 -0.96 0.33 -0.02 0.97 -0.26 0.72 
Male (vs. Female) 0.82 0.07 -0.22 0.66 0.31 0.37 -0.12 0.77 
Duplication * Age 1.05 0.25 1.04 0.34 0.13 0.82 0.11 0.88 
Duplication * Sex -0.86 0.11 0.47 0.44 -0.36 0.39 -0.11 0.82 
EAH external: Eating in the Absence of Hunger (EAH) due to external cues; EAH boredom: EAH due to boredom; EAH fatigue: EAH due to 
fatigue/anxiety; EAH negative: EAH due to negative affect (anger/depression) 
*Random intercept models 
**Random intercept random slope mode
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A10.3:  Random intercept random slope linear mixed model of BMI z-score and 16p11.2 genotype, 
adjusted for age and sex	
Outcome BMI z-score 
 Beta Estimate p-value 
Intercept -0.08 0.84 
Non-carrier (vs. Duplication) 0.56 0.21 
Deletion (vs. Non-carrier) 1.18 0.01 
Age <5 (vs. Age ≥5) 0.39 0.53 
Male (vs. Female) -0.23 0.62 
Non-carrier * Age 1.20 0.15 
Non-carrier * Sex -0.34 0.54 
Deletion *Age 0.13 0.87 
Deletion * Sex 0.23 0.67 





A11: BMI z-score vs. age among duplication carriers at all ages with growth measurements available.  
Box plots depict the median, 25th, and 75th percentile values, and are joined at their median values. 
Whiskers represent 5th and 95th percentile values. Numbers below the graph represent the number of 
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A12: PAGE Study Source Populations 
	
The Atherosclerosis Risk in Communities (ARIC) study 
ARIC is a multi-center prospective study of atherosclerotic disease in European American 
and African American men and women randomly recruited from Forsyth County, NC; Jackson, 
MS; suburban areas of Minneapolis, MN; and Washington County, MD. In total 15,792 
individuals, whose age ranged from 45-64 years at baseline, participated in the baseline 
examination in 1987-1989, with follow-up examinations in approximate 3-year intervals. [157]. All 
3,335 AAs participating in ARIC were genotyped on the Metabochip. 
The Women’s Health Initiative (WHI) study 
The WHI consists of a prospective cohort study as well as three randomized clinical trials 
focused on preventing heart disease, breast and colorectal cancer and osteoporotic fracture 
among postmenopausal women. A total of 161,838 women aged 50–79 were recruited from 40 
clinical centers in the US between 1993 and 1998 [158, 159]. Measurements were normalized to 
correct for laboratory and study effect. All 11,638 AA women who consented to DNA analysis 
were genotyped on the Metabochip or Affymetrix 6.0 SNP arrays. 
The Multiethnic Cohort (MEC) study 
 The MEC is a population-based prospective cohort study of lifestyle and genetic risk 
factors for cancer initiation and progression. The population comprised 215,251 men and women 
in HI and CA aged 45-75, and belonged to five ethnic groups: EAs, AAs, Japanese Americans, 
Latinos, and Native Hawaiians [160]. Enrolment took place between 1993 and 1996, and blood 
specimens were collected from ~67,000 subjects between 1995 and 2004. AA subjects were 
selected for Metabochip genotyping based on availability of biomarkers for cardiovascular risk 
factors or as controls for nested case control studies of type 2 diabetes. 
The Hypertension Genetic Epidemiology Network (HyperGEN) 
 The HyperGEN consists of sibships with multiple hypertensive individuals, as well as their 
other siblings and offspring, identified through population- and community-based studies based in 
AL, NC, MN, and UT. Probands had hypertension with onset before age 60, and had at least one 
hypertensive sibling willing to participate in the study. Recruitment, cross-sectional phenotyping, 
and DNA isolation were completed by 2003. Individuals with Type 1 diabetes or advanced renal 
disease (risk factors for secondary hypertension) were excluded from the study. All 1,264 AAs, 




 GenNet is a family study of hypertension in European Americans (1497 from Tecumseh, 
MI) and AAs (1101 from Maywood, IL). Probands with baseline age 18-50 and blood pressures in 
the upper 20th to 25th percentile for their age and gender were recruited between 1995 and 2003. 
Relatives were enrolled regardless of their blood pressure or hypertension treatment status. All 
AA probands were genotyped on the Metabochip. 





A13: FTO locus SNP summary statistics from the GWAS of >20,000 AAs.  
Modified from Peters et al. [74] 
rsID Position Alt Ref MAF Z-score 
rs6499640 53769677 G A 0.35 -0.25 
rs72803664 53784911 A G 0.11 -0.36 
rs1108102 53789508 A T 0.14 -0.32 
rs1421085 53800954 C T 0.12 3.54 
rs11642015 53802494 T C 0.11 3.47 
rs62048402 53803223 A G 0.12 3.60 
rs1558902 53803574 A T 0.12 3.28 
rs56094641 53806453 G A 0.12 3.57 
rs55872725 53809123 T C 0.11 3.47 
rs1121980 53809247 A G 0.47 1.83 
rs62033400 53811788 G A 0.12 4.41 
rs16945088 53812524 G A 0.29 -0.76 
rs8057044 53812614 G A 0.29 -1.29 
rs17817449 53813367 G T 0.39 1.84 
rs17817497 53815435 C T 0.11 3.16 
rs8050136 53816275 A C 0.44 2.08 
rs113191842 53817318 A G 0.06 2.77 
rs3751812 53818460 T G 0.11 3.25 
rs9939609 53820527 T A 0.48 0.21 
rs9927317 53820996 G C 0.26 3.83 
rs17817712 53821125 G A 0.11 3.28 
rs62033405 53822387 T C 0.12 4.30 
rs79994966 53823727 C T 0.11 4.27 
rs28432761 53823878 C T 0.19 3.29 
rs11647020 53823990 T C 0.2 2.89 
rs11646715 53824007 A G 0.19 3.20 
rs62033406 53824226 G A 0.14 3.00 
rs9941349 53825488 T C 0.19 2.73 
rs56137030 53825905 A G 0.12 4.41 
rs28567725 53826028 C T 0.22 3.59 
rs9931494 53827179 G C 0.19 3.72 
rs10468280 53827479 G A 0.11 3.22 
rs62033408 53827962 G A 0.11 3.28 
rs17817964 53828066 T C 0.12 3.36 
rs62033413 53830055 G C 0.12 4.34 
rs9930506 53830465 G A 0.22 2.72 
rs9933040 53830867 A T 0.22 2.68 
rs9922708 53831146 T C 0.21 2.44 
rs72805611 53831354 T C 0.12 3.20 
rs9922619 53831771 T G 0.19 2.73 
rs7204609 53833605 C T 0.34 -0.76 
rs7188250 53834607 C T 0.12 4.38 
rs72805612 53834608 A G 0.12 4.33 
rs11075993 53837144 T G 0.12 3.12 
rs72805613 53837342 G A 0.12 2.93 
rs8044769 53839135 T C 0.25 -1.50 
rs12149832 53842908 A G 0.12 2.93 
rs11649091 53845169 G T 0.16 3.88 
rs11642841 53845487 A C 0.11 2.72 
rs7191513 53990523 G A 0.46 -0.15 





A14: Metabochip SNP Calling and Quality Control  
 For each study, Metabochip SNPs were called and clustered by the PAGE Data 
Coordinating Center using the GenTrain 2.0 algorithm as well as the GenoSNP genotype calling 
algorithm (Illumina Inc., San Diego, CA). The latter may be more effective for calling rare 
genotypes [161] since it is sample-based as opposed to SNP-based [162]. Study-specific cluster 
definitions based on samples with call rate >95% (ARIC, MEC, WHI) or Illumina cluster definitions 
(GenNet, HyperGEN) were used to call samples, and those with call rate >95% were retained. 
SNPs were excluded as technical failures due to call rate (<0.95), cluster score (<0.6 for ARIC, 
MEC, WHI; <0.7 for GenNet, HyperGEN), cluster separation score (<0.4), replication error rate 
(>2), >1 Mendelian error in the YRI trios, or deviation from Hardy-Weinberg equilibrium (p<10-6). 
There were few discrepancies between GenCall and GenoSNP calls (0.8%) and between PAGE 
and HapMap database YRI calls (0.3% of genotypes and 1.1% of overlapping genotypes). For 







A15: Cumulative proportion of marker sharing between Yoruban (YRI) trios and African 




A16: Functional SNP Annotations 
DHSs mark regions of “open” chromatin accessible to proteins such as transcription 
factors and free of DNA-condensing nucleosomes, and are therefore hallmarks of transcriptionally 
active genomic regions. Maurano et al. [143] performed DNase I mapping genome-wide in 349 
samples, including 333 samples from primary fetal tissues (heart, brain, lung, kidney, small and 
large intestine, muscle, placenta, and skin) and 116 samples from cell lines or sorted blood cells 
(http://www.uwencode.org/proj/Science_Maurano_Humbert_et_al/). Thurman et al. [144] defined 
an additional set of regions as DNase I hypersensitive in 53 samples 
(http://ftp.ebi.ac.uk/pub/databases/ensembl/encode/integration_data_jan2011/byDataType/openc
hrom/jan2011/fdrPeaks/).  
Genome-wide functional annotations of chromatin state are also available for each of six 
primary cell lines: gm12878 (lymphoblastoid), h1hesc (embryonic stem cells), helas3 (cervical 
cancer), hepg2 (liver carcinoma), huvec (umbilical vein endothelial cells), and k562 (chronic 
myelogenous leukemia). These chromatin states were derived from chromatin 
immunoprecipitation assays for multiple histone modifications and general transcription factors, 
as well as chromatin accessibility assays, and were systematically integrated into seven non-
overlapping genomic states by Hoffman et al. [145]: predicted promoter regions including 
transcription start site (TSS), predicted promoter flanking region (PF), predicted enhancer (E), 
predicted weak enhancer (WE), CTCF-enriched element (CTCF), predicted transcribed region 
(T), and predicted repressed or low-activity region (R) 
(http://ftp.ebi.ac.uk/pub/databases/ensembl/encode/integration_data_jan2011/byDataType/segme
ntations/jan2011/hub/). 
The Roadmap consortium used 12 histone modifications marks to predict a 25-chromatin state 
model for 127 reference epigenomes from the Roadmap Epigenomics and ENCODE projects, 






A17: List of 127 epigenomes (111 by the Roadmap Epigenomics program [E001-E113], 16 by ENCODE [E114-E129])  
Adapted from [128]. 
EID: Reference epigenome identifier Epigenome Name Sample Type 
(Biological Material) 
Cell Type/Tissue Group 
(Anatomical Location) 
E001 ES-I3 cells Primary cultures ES cell 
E002 ES-WA7 cells Primary cultures ES cell 
E003 H1 cells Primary cultures ES cell 
E004 H1 BMP4 derived mesendoderm ES cell derived ES-deriv. 
E005 H1 BMP4 derived trophoblast ES cell derived ES-deriv. 
E006 H1 derived mesenchymal stem cells ES cell derived ES-deriv. 
E007 H1 derived neuronal progenitor cultured cells ES cell derived ES-deriv. 
E008 H9 cells Primary cultures ES cell 
E009 H9 derived neuronal progenitor cultured cells ES cell derived ES-deriv. 
E010 H9 derived neuron cultured cells ES cell derived ES-deriv. 
E011 HUES64 derived CD184+ endoderm ES cell derived ES-deriv. 
E012 HUES64 derived CD56+ ectoderm ES cell derived ES-deriv. 
E013 HUES64 derived CD56+ mesoderm ES cell derived ES-deriv. 
E014 HUES48 cells Primary cultures ES cell 
E015 HUES6 cells Primary cultures ES cell 
E016 HUES64 cells Primary cultures ES cell 
E017 IMR90 fetal lung fibroblasts Cell line IMR90 
E018 iPS-15b cells Primary cultures iPSC 
E019 iPS-18 cells Primary cultures iPSC 
E020 iPS-20b cells Primary cultures iPSC 
E021 iPS DF 6.9 cells Primary cultures iPSC 
E022 iPS DF 19.11 cells Primary cultures iPSC 
E023 Mesenchymal stem cell derived adipocyte Primary cultures Mesench. 
E024 ES-UCSF4 cells Primary cultures ES cell 
E025 Adipose-derived mesenchymal stem cells Primary cultures Mesench. 
E026 Bone marrow derived MSCs Primary cultures Mesench. 
E027 Breast myoepithelial Primary cells Epithelial 
E028 Breast vHMEC mammary epithelial Primary cultures Epithelial 
E029 Primary monocytes (from PB) Primary cells HSC & B cell 
E030 Primary neutrophils (from PB) Primary cells HSC & B cell 
E031 Primary B cells from cord blood Primary cells HSC & B cell 
E032 Primary B cells (from PB) Primary cells HSC & B cell 
E033 Primary T cells from cord blood Primary cells Blood & T cell 
E034 Primary T cells from primary blood (from PB) Primary cells Blood & T cell 
E035 Primary haematopoietic stem cells (HSCs) Primary cells HSC & B cell 
E036 Primary HSCs short term culture Primary cells HSC & B cell 
E037 Primary T helper memory cells (from PB) Primary cells Blood & T cell 




E039 Primary T helper naive cells (from PB) Primary cells Blood & T cell 
E040 Primary T helper memory cells (from PB) Primary cells Blood & T cell 
E041 Primary T helper cells PMA-I stimulated Primary cells Blood & T cell 
E042 Primary T helper 17 cells PMA-I stimulated Primary cells Blood & T cell 
E043 Primary T helper cells (from PB) Primary cells Blood & T cell 
E044 Primary T regulatory cells (from PB) Primary cells Blood & T cell 
E045 Primary T cells effector/memory enriched (PB) Primary cells Blood & T cell 
E046 Primary natural killer cells (from PB) Primary cells HSC & B cell 
E047 Primary T CD8+ naive cells (from PB) Primary cells Blood & T cell 
E048 Primary T CD8+ memory cells (from PB) Primary cells Blood & T cell 
E049 Mesenchymal stem cell deriv. chondrocyte Primary cultures Mesench. 
E050 Primary HSCs G-CSF-mobilized female Primary cells HSC & B cell 
E051 Primary HSCs G-CSF-mobilized male Primary cells HSC & B cell 
E052 Muscle satellite Primary cultures Myosat. 
E053 Cortex derived neurospheres Primary cultures Neurosph 
E054 Ganglion eminence derived neurospheres Primary cultures Neurosph 
E055 Foreskin fibroblast Primary cultures Epithelial 
E056 Foreskin fibroblast Primary cultures Epithelial 
E057 Foreskin keratinocyte Primary cultures Epithelial 
E058 Foreskin keratinocyte Primary cultures Epithelial 
E059 Foreskin melanocyte Primary cultures Epithelial 
E061 Foreskin melanocyte Primary cultures Epithelial 
E062 Primary mononuclear cells (from PB) Primary cells Blood & T cell 
E063 Adipose nuclei Primary tissues Adipose 
E065 Aorta Primary tissues Heart 
E066 Liver Primary tissues Other 
E067 Brain angular gyrus Primary tissues Brain 
E068 Brain anterior caudate Primary tissues Brain 
E069 Brain cingulate gyrus Primary tissues Brain 
E070 Brain germinal matrix Primary tissues Brain 
E071 Brain hippocampus middle Primary tissues Brain 
E072 Brain inferior temporal lobe Primary tissues Brain 
E073 Brain dorsolateral prefrontal cortex Primary tissues Brain 
E074 Brain substantia nigra Primary tissues Brain 
E075 Colonic mucosa Primary tissues Digestive 
E076 Colon smooth muscle Primary tissues Smooth muscle 
E077 Duodenum mucosa Primary tissues Digestive 
E078 Duodenum smooth muscle Primary tissues Smooth muscle 
E079 Oesophagus Primary tissues Digestive 
E080 Fetal adrenal gland Primary tissues Other 
E081 Fetal brain male Primary tissues Brain 
E082 Fetal brain female Primary tissues Brain 




E084 Fetal intestine large Primary tissues Digestive 
E085 Fetal intestine small Primary tissues Digestive 
E086 Fetal kidney Primary tissues Other 
E087 Pancreatic islets Primary tissues Other 
E088 Fetal lung Primary tissues Other 
E089 Fetal muscle trunk Primary tissues Muscle 
E090 Fetal muscle leg Primary tissues Muscle 
E091 Placenta Primary tissues Other 
E092 Fetal stomach Primary tissues Digestive 
E093 Fetal thymus Primary tissues Thymus 
E094 Gastric Primary tissues Digestive 
E095 Left ventricle Primary tissues Heart 
E096 Lung Primary tissues Other 
E097 Ovary Primary tissues Other 
E098 Pancreas Primary tissues Other 
E099 Placenta amnion Primary tissues Other 
E100 Psoas muscle Primary tissues Muscle 
E101 Rectal mucosa donor 29 Primary tissues Digestive 
E102 Rectal mucosa donor 31 Primary tissues Digestive 
E103 Rectal smooth muscle Primary tissues Smooth muscle 
E104 Right atrium Primary tissues Heart 
E105 Right ventricle Primary tissues Heart 
E106 Sigmoid colon Primary tissues Digestive 
E107 Skeletal muscle male Primary tissues Muscle 
E108 Skeletal muscle female Primary tissues Muscle 
E109 Small intestine Primary tissues Digestive 
E110 Stomach mucosa Primary tissues Digestive 
E111 Stomach smooth muscle Primary tissues Smooth muscle 
E112 Thymus Primary tissues Thymus 
E113 Spleen Primary tissues Other 
E114 A549 EtOH 0.02pct lung carcinoma Cell line ENCODE 2012 
E115 Dnd41 T cell leukaemia Cell line ENCODE 2012 
E116 GM12878 lymphoblastoid Primary cultures ENCODE 2012 
E117 HeLa-S3 cervical carcinoma Cell line ENCODE 2012 
E118 HepG2 hepatocellular carcinoma Cell line ENCODE 2012 
E119 HMEC mammary epithelial Primary cultures ENCODE 2012 
E120 HSMM skeletal muscle myoblasts Primary cultures ENCODE 2012 
E121 HSMM-derived skeletal muscle myotubes Primary cultures ENCODE 2012 
E122 HUVEC umbilical vein endothelial Primary cultures ENCODE 2012 
E123 K562 leukaemia Primary cultures ENCODE 2012 
E124 Monocytes-CD14+ RO01746 Primary cells ENCODE 2012 
E125 NH-A astrocyte Primary cultures ENCODE 2012 




E127 NHEK-epidermal keratinocyte Primary cultures ENCODE 2012 
E128 NHLF lung fibroblast Primary cultures ENCODE 2012 



















rs6499640 0 1 0 1 0 1 
rs72803664 0 1 0 1 0 0 
rs1108102 0 0 0 0 0 0 
rs1421085 0 0 0 0 0 0 
rs11642015 0 0 0 0 0 0 
rs62048402 0 0 0 0 0 0 
rs1558902 0 0 0 0 0 0 
rs56094641 0 0 0 0 0 0 
rs55872725 0 0 0 0 0 0 
rs1121980 0 0 0 0 0 0 
rs62033400 0 0 0 0 1 1 
rs16945088 0 0 0 0 0 0 
rs8057044 0 0 0 0 0 0 
rs17817449 0 0 0 0 0 0 
rs17817497 0 0 0 0 0 0 
rs8050136 0 1 0 0 0 1 
rs113191842 0 1 0 1 0 0 
rs3751812 0 0 0 0 0 0 
rs9939609 0 1 0 1 0 1 
rs9927317 0 1 0 1 0 1 
rs17817712 0 1 0 1 0 1 
rs62033405 1 0 1 0 0 0 
rs79994966 0 0 0 0 0 0 
rs28432761 0 0 0 0 0 0 
rs11647020 0 0 0 0 0 0 
rs11646715 0 0 0 0 0 0 
rs62033406 0 0 0 0 0 0 
rs9941349 0 0 0 0 0 0 
rs56137030 0 0 0 0 0 0 
rs28567725 0 0 0 0 0 0 
rs9931494 0 0 0 0 0 0 
rs10468280 0 0 0 0 0 0 
rs62033408 0 0 0 0 0 0 
rs17817964 0 0 0 0 0 0 
rs62033413 0 0 0 0 0 0 
rs9930506 0 0 0 0 0 0 




rs9922708 0 1 0 0 0 1 
rs72805611 0 1 0 0 0 1 
rs9922619 0 0 0 0 0 0 
rs7204609 0 1 0 1 0 1 
rs7188250 0 1 0 1 0 1 
rs72805612 0 1 0 1 0 1 
rs11075993 0 0 0 1 0 0 
rs72805613 0 0 0 1 0 0 
rs8044769 0 0 0 0 0 1 
rs12149832 0 0 0 0 0 0 
rs11649091 0 0 0 0 0 0 
rs11642841 0 0 0 0 0 0 
rs7191513 0 0 0 0 0 0 
rs9932411 0 0 0 0 0 0 
1s indicate tissue-specific annotations that overlap with a given SNP 
EnhAc: Primary H3K27ac possible Enhancer; Tx5: Transcribed – 5’ Preferential 
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